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Abstract
Outpatient chemotherapy infusion is one of the most common forms of treatment
used to cure, control, and ease symptoms of cancer. Patients who require outpatient
chemotherapy infusion undergo lengthy and physically demanding infusion sessions
over the course of their treatment. While the frequency and duration of visits vary by
patient, drug, and cancer type, most patients will require several treatments over the
course of months or years to complete their regimen/treat their disease. Receiving
infusion is just one part of the complex treatment process. Patients may have their
blood work done, wait for the results to process, visit their oncologist, wait on their
order to be placed by their oncologist and prepared by the pharmacy, and then have
the infusion administered by infusion clinic staff. Each step introduces randomness
which can lead to propagated delays. These delays negatively affect patients as well
as clinical operation cost and staff workload.
We focus on optimizing drug preparation at the pharmacy to reduce patient
delays. Drugs can be prepared the morning before patients arrive to prevent the
patient from waiting the additional time needed to prepare their prescribed drugs
in addition to any other wait time incurred during peak pharmacy hours. However,
patients scheduled for outpatient chemotherapy infusion sometimes may need to
cancel at the last minute even after arriving for their appointment (i.e. patient may
xiv
be deemed too ill to receive treatment). This results in the health system incurring
waste cost if the drug was made ahead since the drugs are patient specific and have
a short shelf life. Infusion centers must implement policies to balance this potential
waste cost with the time savings for their patients and staff. In support of this effort,
this dissertation focuses on methods and strategies to improve the process flow of
chemotherapy infusion outpatients by optimizing pharmacy make-ahead policies.
We propose using three different methods which build upon each other. First
we develop a predictive model which utilizes patient-specific data to estimate the
probability that a patient will defer or not show for treatment on a given day.
Generally, the ability to generate high-quality predictions of patient deferrals can
be highly valuable in managing clinical operations, such as scheduling patients,
determining which drugs to make before patients arrive, and establishing the proper
staffing for a given day. We also introduce how the patient-specific probability of
deferral can help determine a “general rule of thumb” policy for what should be
made ahead on a given day.
Next we utilize these probabilities in two integer programming models. These
multi-criteria optimization models prioritize which and how many drugs to make
ahead given a fixed window of time. This is done with the dual objectives of reducing
the expected waste cost as well as the expected value of reduced patient waiting time.
Lastly, we utilize simulation to better quantify the impact of our proposed
policies. We show that making chemotherapy drugs ahead of an infusion appointment
not only benefit the patient they are prescribed for but also subsequent patients due
to the decrease load (i.e., reduced blocking) on the pharmacy system as a whole.
xv
Each method utilizes electronic medical record data from the University of Michigan






Cancer is the second leading cause of death in the United States (U.S.), with the
number of estimated annual cases increasing from 1.3 million in 2005 to 1.8 million
in 2019 [1]. With most patients undergoing a combination of chemotherapy infusion
(i.e., intravenously-administered medication), radiation therapy, and surgery, over
half of cancer patients in the U.S. will require some form of chemotherapy.
Additionally, cancer treatments continue to advance and increase in complexity.
This results in an increase in the frequency of patient infusion visits for a given
treatment regimen as well as an increase in cancer survivors. Many of these cancer
survivors need continued visits to help in the prevention and detection of new or
recurrent cancers. They also may need treatment for secondary health problems
caused by the chemotherapy. Aside from complexity, as the FDA approves more
chemotherapy drugs with increased survival rates, even more patients are opting into
chemotherapy [2]. Consequently, this increased demand of patients at outpatient
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chemotherapy infusion centers leads to increased patient waiting time, patient
dissatisfaction, and overworked staff. Furthermore, patient and nurse safety becomes
a concern as demand increases. The risk of the hazardous chemotherapy agents
spilling on patients or nurses increases when the nurses are overworked [3], [4], [5].
Therefore, any process improvement on the system has the potential for multifaceted
benefits [6].
1.2 Chemotherapy Infusion Drugs
Often, chemotherapy is a drug mixed in solution that is used to treat one’s
disease. Most patients receive chemotherapy treatment in conjunction with radiation
therapy or surgery which focus on removing cancer cells from certain areas in the
body. There are over 100 chemotherapy drugs approved for use in the U.S. including
some oral drugs [7]. Broadly, these drugs target cells at various stages of the new cell
replication process or on a specific and unique molecular target [8]. Although cancer
cells grow more rapidly than most healthy cells, chemotherapy drugs may damage
both cancer and healthy cells that rapidly divide. The balance between treating a
patient’s cancer and managing the side effects of such treatment is principal to the
role of an oncologist.
While the primary goal of using chemotherapy infusion is to kill cancer cells, there
are two main reasons an oncologist prescribes chemotherapy. (1) Curative intent
chemotherapy can be given alone as in the case when the cancer is particularly
sensitive to the effects of chemotherapy (i.e. Lymphoma or Luekemia) or in
combination with surgery or radiation for those that are not. It is also used before
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surgery or radiation therapy to shrink a tumor (i.e., neoadjuvant therapy), after
surgery to help kill any remnant cancer cells (i.e., adjuvant therapy), or in conjunction
with other treatments if a patients’ cancer returns. [9] (2) If the cancer is too far
progressed or no longer seen as medically curable, then the goal may focus on
palliating the disease. Chemotherapy is used to shrink tumors or stop the cancer from
spreading which can increase a patient’s quality and length of life. There are cases
where the cancer will never go away (e.g., low grade lymphoma) but can be managed
through treatment similar to other chronic diseases such as diabetes. Oncologists
also might recommend chemotherapy to ease the symptoms caused by the cancer.
Again, the goal of the chemotherapy in this case is to improve the quality of life for
a patient (e.g. shrink a tumor that may be pressing against a nerve).
Due to the complexity of treatment and nature of chemotherapy drugs, many
factors are considered when determining what type of drug a patient receives, the
frequency, and the dose. Drug choice is mainly driven by the type of cancer,
stage/progression, patient’s age, patient’s current health state, and the patient’s
previous cancer treatment history. While doses are typically based on the patient’s
body weight or body surface area, some must be adjusted to better accommodate
patients with other health complications or to reduce interference with other ongoing
medications or treatments. The chemotherapy dose must stay within the narrow
margin of being safe yet effective. Similarly, the frequency at which these drugs are
given is determined based on multiple factors. The main goal is to allow sufficient
time for normal cells to recover from drug side effects. The frequency magnitude can
vary between days and weeks.
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1.2.1 Make-ahead Drugs
Most pharmacies cannot stockpile prepared chemotherapy agents due to their
limited viability. Some drugs must be administered immediately while others can
last in storage for up to 24 hours. All chemotherapy drugs are assigned a hang-by
time which indicates how many hours the infusion center has until they must start
administering the drug (i.e., similar to a sell-by date rather than an expiration date).
In this dissertation, we show chemotherapy drugs can be prepared (i.e.,
compounded) ahead of time to reduce the time a patient waits for their drug
to be made similar to [10]. The compounding process consists of combining the
chemotherapy drug agent with a solution (such as saline or dextrose). Some drugs
also require additional time for the agent to settle in the solution. Depending on
the drug, this compounding process can take up to an hour to complete for a single
dose after all safety protocols are followed. However, given the inherent nature of the
sick patient population served, there is a risk of making a last minute cancellation
due to not being well enough for treatment after arriving for their appointment [11].
Consequently, if their drug was made ahead, the infusion center could incur a waste
cost. However, if there are multiple patients scheduled to receive the same dose of the
drug then the subsequent patient would be able to utilize it if the intended patient
defers and if the drug remains viable. Infusion centers must implement policies that
balance this potential waste cost with the time savings for their patients and staff.
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1.2.2 Chemotherapy Infusion Drug Cost
When discussing the cost of chemotherapy infusion drugs, there are multiple
perspectives to take and factors to consider. This includes what the hospital pays
to stock the drug, what is billed to insurance companies, and what the patients
get billed. However this doesn’t include the administration cost, any facility fees,
or cost associated with compounding the drug (i.e., technician labor cost). This
research defines any cost as the amount of money that the hospital would have paid
for the drug had it been used. While the hospital buys the stock drugs in standard
vial or unit sizes, once compounded the cost range for a single dose of a drug is
between $10-$25,000 (Note: These cost are based on infusion pharmacy data from
the University of Michigan Rogel Cancer Center). With such high cost, hospital
administrators are reluctant to approve making all patient drugs ahead of time due
to the fear of waste caused by last minute cancellation out of the patients control.
The hospital cannot bill a patient or their insurance if they are not well enough to
receive treatment.
1.3 University of Michigan Rogel Cancer Center (UMRCC)
At UMRCC, chemotherapy infusion outpatient visits consist of getting blood
work done in the phlebotomy lab, seeing their oncologist, waiting for the pharmacy
to prepare their chemotherapy drug, and receiving their infusion. However, recurring
patients do not always have a clinic visit as seen in Figure 1.1. Although patients are
not directly involved with the pharmacy process, the drug preparation phase of their
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visit is a key contributor to the overall time a patient spends in the infusion center.
While a patients drug is bering prepared, they are either waiting in the waiting room
or infusion area being prepared for treatment. Therefore a shorter turnaround-time
(TAT) in the pharmacy means a shorter overall time in the system for the patient.
Figure 1.1: Flow of outpatients and their information based on observations and
interviews conducted with the medical staff at UMRCC
The patient’s orders are only sent to the pharmacy once the patient finishes their
clinic visit or checks into the infusion area. The goal is to keep the TAT under 1
hour for each patient. However, through observation and historical data, we see that
the TAT can be as long as 2 hours.
As seen in Figure 1.2, drug orders must go through a series of safety checks,
compounding, and labeling to ensure the safety of patients and healthcare providers.
Our focus is to improve the drug TAT in the pharmacy and in turn reduce the overall
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Figure 1.2: Drug order process flow based on observations and interviews conducted
with the pharmacists at UMRCC
1.4 Dissertation Summary
In this dissertation, we focus on improving outpatient infusion center pharmacies’
efficiency by proposing methods to generate and evaluate make-ahead chemotherapy
drug policies (i.e., pre-mix policies) to ensure the drugs are available as soon as
the patient is deemed ready to receive them. However when deciding which drugs
to pre-mix, the decision maker must evaluate the trade-off between the potential
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time saved by making the drugs and the risk of waste if the patient defers (i.e., last
minute cancellation due to provider deeming patient not well enough or through self
election). We discuss three methods which work in conjunction with each other as
seen in Figure 2.2.
Figure 1.3: Work flow for all methods discussed in this dissertation
In Chapter 2 we discuss reasons for last minute cancellations and then develop a
predictive model to better determine the chance a patient will defer their treatment.
These high-quality predictions directly feed into determining expected time savings
and expected waste cost if a particular drug is pre-mixed. The predictions can also be
utilized when scheduling patients, establishing proper staffing both in the pharmacy
and infusion area, and our focus of determining which drugs to pre-mix.
In Chapter 3 we utilize these probabilities in a binary integer programming model
to determine the most advantageous set of drugs to pre-mix. Given a fixed window
of time, our model evaluates a multi-criteria objective by maximizing expected dollar
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value of reduced wait while minimizing the expected waste cost. This pre-mix window
can either be early in the morning, before patients arrive, or late in the evening to
prepare drugs for the next day.
Lastly in Chapter 4 we use discrete-event simulation to evaluate and compare
various make-ahead policies and their broader effects on the infusion center as a
whole. Here we show that pre-mixing chemotherapy drugs not only benefit the
patient they are prescribed but for subsequent patients as well, due to decreasing the
pharmacy work load during peak demand times. We evaluate randomness associated
with patient arrivals and the various process steps during the compounding process.
These tools for pre-mixing chemotherapy drugs at the UMRCC can be beneficial
in regard to decreasing patient wait times and saving nurse overtime cost. This
dissertations suggest that our approach will not only help reduce patient waiting
times at the UMRCC and other Cancer Centers, but may stand as the foundation
for the development of decision support software to help other pharmacies organize
drug preparation. Also, this approach may be relevant in other areas of healthcare
where there are interactive stages with unpredictability. An example might be an
emergency department starting to prepare an inpatient bed prior to a patient being
admitted.
1.5 Key Contributions
In Chapter 2 we develop the first prediction model to determine the probability
of a patient deferral (i.e., last minute cancellation) in an outpatient chemotherapy
infusion setting. All previous efforts focused on no-show predictions. We
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also demonstrate a comparative procedure as well as a unique temporal data
cross-validation to compare multiple models and determine which is best for our
data set. We discuss these steps which can be applied to any datasets looking to
predict patient deferrals.
In Chapter 3 we develop an optimization model focusing on pre-mixing
chemotherapy drugs. We discuss two variants of our problem and illustrate
how to formulate a deterministic IP model where the decision variables are both
interdependent and time dependent.
In Chapter 4 we incorporate our predictions from Chapter 2 in a discrete-event
simulation to better represent the effects of the drug make-ahead process while
considering the chance of patient deferring treatment. This tool can evaluate any
pre-mix/make-ahead chemotherapy drug policy at an outpatient infusion center.
We also show while these methods can stand independently, they work in





Patients scheduled for outpatient infusion sometimes may be deferred for
treatment (i.e. last minute cancellation) after arriving for their appointment. This
can be due to a secondary illness, not meeting required treatment parameters (e.g.
white blood cell counts), or other medical complications. In most cases an oncologist
or nurse order a deferral when the patient has not recovered sufficiently from the
prior chemotherapy. After a clinic visit, the oncologist might suggest a treatment
plan change as well which would result in a wasted drug if it was made ahead. This
might results from a patient progressing on current treatment and another treatment
is recommended but can’t be given that day. While unlikely, a patient may self elect
to defer treatment due to social support or other personal reasons. This includes
arranging a ride home, absence of planned family support, etc.(possibly look up
a connection to mental health here. Additionally a patient may or may not have
progressed on current treatment and decides not to continue but to receive palliative
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care.The ability to generate high-quality predictions of patient deferrals can be highly
valuable in managing clinical operations, such as scheduling patients, determining
which drugs to make before patients arrive, and establishing the proper staffing for
a given day.
At the University of Michigan Rogel Cancer Center (UMRCC), more than 50,000
infusion treatments are performed annually with an increase in patient volume of 5%
per year [12]. At every step during a patient’s visit (blood draw, clinic, pharmacy,
infusion, etc.), there is variability, which can cause disruptions that lead to patient
delays and overtime for the infusion nurses.
While these disruptions can originate from many sources, one of the biggest
impacts on infusion clinics is when patients no-show or defer their treatment.
Unlike other outpatient services, which can have up to a 41% no-show rate [13],
patient no-shows are typically not as large of an issue regarding chemotherapy
infusion appointments. At UMRCC, for example, only approximately 2% of infusion
appointments in 2015 resulted in no-shows; anecdotally, it is thought that patients
generally understand the importance of their chemotherapy treatment and will do
everything in their power to make sure they arrive for their appointment. On the
other hand, although patients show for their appointments, once they arrive they may
be deemed too ill for treatment. Additionally, patients may make the decision during
their pre-infusion clinic visit to transition to palliative care. Similarly, their oncologist
may change their treatment plans based on their response to prior treatments. We
refer to these situations as patient treatment deferrals, which are a common source
of last minute cancellations. At UMRCC, nearly 47% of patients have at least one
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of their infusions deferred over the course of their treatment.
Current prediction models in outpatient care primarily focus on determining
patient no-shows to help determine more advantageous over-booking
policies [14] [15] [16]. Most authors had an objective to improve and/or implement
over booking policies/appointment rescheduling. Alaeddini, A, et. al. developed
a hybrid model for this exact purpose using a test case from the Veteran Affairs
(VA) hospital in Detroit, MI. They presented first a multinomial logistic regression
which fed their Bayesian inference model to predicted no-show, cancellation,
and completed appointment probabilities. (It was not made clear if a same-day
cancelation was classified as a no-show since in most cases this appointment would
not have been filled.) They also made comparisons with models such as decision
tree, Bayes update, Bayes net, Neural network, boosting, etc. However, they did not
use the same holdout for all compared models. (Some held out 2/3 while other only
1/3). They also did not indicate a repeated holdout was used to check the variance
of the presented models performance [17]. Daggy, J., et. al. also worked with the
VA hospital system where they specifically focused on predicting a patient no-show
model. They had three years of data for model fitting and testing. They fit a binary
logistical regression model without performance comparisons to other classification
models. They also had the objective to improve scheduling policies and reduce idle
time for physicians due to patient no-shows [18]. Huang, Y. and Hanauer, D.A. also
implemented a binary logistical regression model to improve overbooking policies at
the University of Michigan Hospital. Similar to others, they utilize both scheduling
and demographic data to help predict patient no-show probabilities, [19]. Binary
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logistical regression models seem to be the most popular in the literature but are
not commonly compared to other methods to prove they have the best predictive
performance.
Since patient no-shows are not as prominent in outpatient chemotherapy infusion,
our binary prediction models will focus on predicting patient deferrals. Fuentes,
S., & Frdin, J. E. also showed that patient deferrals make up the majority of
patient cancellations at an outpatient infusion center. They conducted a study
to determine the size of this cancellation problem at the Department of Oncology
at Karolinska University hospital in Stockholm. They analyzed the frequency of
late cancellations as well as the reasons for them. Patients were organized into
three categories of treatment indications: curative treatment, adjuvant therapy, and
palliative therapy. The cause of late cancellations were classified in five categories:
hematological toxicity, other toxicity, patient choice, administrative reasons, and
deteriorated performance status. Of the 2948 bookings (1460 patients) during the
four-week period, 383 (13%) were cancelled late. For palliative, there were 16%
late cancellations; for adjuvant, 9%; for curative, 8%. Patient deterioration was the
dominant reason for late cancellations of palliative treatment, whereas hematological
toxicity was the dominant reason for late cancellations of adjuvant treatment. Patient
deterioration is the dominating cause, overall (51% of total cancellation) [11]. In our
model we consider these deterioration and hematological toxicity cases as patient
deferrals. This can result from not meeting required lab parameters to receive
treatment or being deemed too ill by a nurse or oncologist. These reasons are also
supported by the expert opinions of the oncologist at UMRCC.
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The presented models utilize demographic, treatment, and patient scheduling
data to determine the probability that a patient will not show for or defer treatment
on a given day. This chapter focuses on the model selection/comparison process.
This information can then be utilized when scheduling patients, determining which
drugs to make-ahead, and determining the proper staffing for a given day. In
the following section, we introduce all prediction models explored including all
performance comparisons. We follow similar procedures found in the literature for
binary classification model comparison [20] [21].
The remainder of this chapter focuses on an outpatient chemotherapy clinic where
we want to predict the patient deferrals (i.e. the patient arrives for their appointment
but is unfit to receive treatment) and no shows. Also, we are more interested in these
predicted probabilities to help determine which drugs we should make-ahead of time
rather than over booking polices for patients in infusion.
2.2 Methods
2.2.1 Data Description
Our patient data was provided by UMRCC. Each patient encounter (both
completed and canceled) is stored in the University Michigan Health Systems’
(UMHS) version of Epic, an electronic medical record called MiChart. We used all
available outpatient chemotherapy infusion visits from January 2, 2015 - December
31, 2015 (N=28919) with 3,522 total unique patients being seen (some of them for
multiple treatments). This excludes 1,266 encounters due to missing data from one
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patient not providing their zip code and the rest not having a treatment protocol
available. We attribute this from our data coming from two different systems and
not having a one to one mapping of treatment protocols and patient scheduling
information. We did not find any commonalities between patients with missing
data regarding their demographics or their scheduling information discussed in this
section.
The scheduling data includes the patients completion status (completed, cancel,
no-show), age, sex (Male, Female), scheduled appointment length, date appointment
made, date appointment completed, and date appointment cancelled. We then were
able to append calculated columns for the total number of previous visits, total
number of previous cancelations, numbers of days since the last cancelation, and
number of days since the last visit. Then based on each patient’s Medical Record
Number (MRN), we were able to include additional demographics such as marital
status, race, ethnicity, zip code, and the last recorded BMI. Table 2.1 displays the
summary statistics for all continuous variables.
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195.6 133.2 30 780
Age Patient’s age in years 59 13.6 16 95
Total Previous Cancellation
Number of cancellation
since the patient’s last
completed visit
0.8 1.4 0 21
Days since Last Cancellation
Number of days since
the patient’s last
cancelled visit
27.3 59.5 0 504
Total Previous Visits
Number of the patient’s
previously completed
visits
8.4 9.2 0 83
Days since Last Visit
Number of days since
the patient’s last
completed visit




28 6.8 12.7 78.7
Table 2.1: Summary statistics of continuous predictors
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Factor Description Levels
Status (Response) Appointment completed or deferred/no-show 2
Sex Either male or female 2
Race
Patient’s Race: White or Caucasian (WC), Black or
African American (BA), Asian, American Indian and
Alaska Native (AA)/Native Hawaiian and Other Pacific








Patient’s Marital Status: Single, Married, Legally




The various treatment protocol a patient is prescribed
by an oncologist. This consists of the type of




Region of the U.S. that the patient’s permanent address
is in.
10
Table 2.2: Summary of factors used in our models
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Due to the large number of unique zip codes, we decided to only incorporate the
region for our patients into our models (i.e. the first digit of the zip code). We also
considered using the county code (i.e. first 3 digits) but again encountered over 67
counties, and this exceeds the number of factor levels some statistical methods (e.g.
Random Forest) can handle. In Appendix A.1 we illustrate the region breakdown
for our dataset. Table 2.2 provides details for all of the factors considered. We note
that while we only considered 51 patient treatment protocols, there are over 300
unique treatment protocols (many are research drugs and/or different variants in
dosing for common drugs). In order to reduce this factor to a reasonable amount
of categories, we only considered levels with at least 150 patient encounters in 2015
with that protocol name and grouped the rest in an ”other” category. We note that
with additional clinical guidance to create groupings of treatment protocols, we can
further reduce the number of treatment protocol factors considered in our prediction
model which might increase the variables’ significance.
2.2.2 Tested Models
We present the results of seven different types of binary classification models
to predict the probability of a patients appointment status: completed (1)
or deferred/no-show (0) from the UMRCC patient data. These models were
chosen based on popularity for binary classification problems and general reported
performance. Each model will be described in the subsequent sections and compared
against the Null model which assigned the empirical probability of deferral to each
patient visit. Due to the temporal nature of the data, we had to carefully design
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our holdout analysis (i.e. determine which data to train our model with and which
to reserve for validating the model). Specifically we cannot train our model on
a patient’s appointment which occurred later than the appointment we plan to
predict. We first sorted the appointments by date. Then we held out the last
1000 entries for final validation (Dec 18, 2015-Dec 31, 2015). In the holdout loop, 90
consecutive days were randomly selected to train. The next consecutive 30 days were
used for testing the prediction. All models were tested with the original training
sets as well as an oversampled dataset to help compensate for our unbalanced
classification problem (i.e. many more completed appointments than treatment
deferral/no-shows). We note other data re-sampling methods (e.g synthetic data
generation, stratified sampling) exist but can be difficult to implement with such a
high number of levels for the categorical variable such as in our problem. Due to
the large numbers of categories for protocol names, we were unable to utilize under
sampling and a combination of both under and over sampling effectively.
All models were fitted in R version 3.0.2 run through RStudio software Version
0.99.903 using a 2.5 GHz Intel Core i7 processor with 16 GB of RAM. Total
computational time for all models in the holdout loop was approximately six hours.
(We summarize the models below with more details in the supplemental material.)
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2.3 Results and Discussion
2.3.1 Model Comparison
We tested two different groups of variables with all of the models. M1 included
protocol ID while M2 did not. Since protocol ID has such a large number of levels,
it significantly increases the solve time of our prediction models. Table 2.3 consists
of all tested models in our holdout analysis. Our goal is to determined the simplest
yet most accurate prediction model in this study.
Models Name Variable Selection Model Formula
Null None None
GLM 1 Full M1
GLM 2 Step M1
CART 1 Full M1
CART 2 Var. Importance M1
CART 3 Full M2
Bag 1 Full M1
Bag 2 Var. Importance M1
Bag 3 Full M2
RF 1 Full M1
RF 2 Var. Importance M1
RF 3 Full M2
MARS 1 Full M1
MARS 2 Full M2
BART 1 Full M1
BART 2 Full M2
Table 2.3: All tested models: Full indicates all variables were selected from Table 2.2
and 2.1 in the main text, Step indicates a stepwise selection based on AIC reduction
was used in R, Variable importance indicates that variable selection was completed
by removing all variables with an overall importance less than or equal to 0, M1
includes all variables while M2 includes all variables except protocol ID
For our model comparison, we used AUC from our receiver operation
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characteristic (ROC) curves, Brier score, and F1 score as our out-of-sample
prediction error measure. All of these methods are commonly used for predictive
modeling in the healthcare setting as seen in [20], [21], and [22]. We note that
AUC is generally considered a more accurate measure of prediction than simply
computing prediction accuracy [23]. However, it has also been shown that AUC
can be less precise compared to actual population metrics when dealing with large
samples or unbalanced samples [24]. Therefore we consider the Brier score since it
directly measure the accuracy of the predicted probabilities. We also measure the
F1 score since it considers both the precision (i.e. positive predictive value) and
recall (i.e. sensitivity)
After completing our 50-fold repeated holdout, we noticed oversampling caused
extremely poor performance in our full Bagged CART and oversample Neural Net
models (which performed worse than the Null model with all three error measures).
Similarly the model performance for oversampling with GLM 2, GLM 3, Bag 2, Bag
3, RF 1,RF 2, Bart 1, and Bart 2 were very close to the Null model. We later saw
the standard sample RF 1 and RF 2 performed poorly as both Brier and F1 scores.
These were excluded from the rest of our analysis. We then present the out of sample
predictive AUC, Brier score, and F1 score for the rest of the considered models
in Figure 2.3.1. Through observation it was clear CART 2 and 3 had very high
variance as well as poor prediction performance. We then observe BART, MARS,
RF, and Bag 3 models seem to outperform all other tested models. In ordered
to determine if their higher performance is significant, we conducted a pairwise
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t-test with a null hypothesis that the AUC of the two models are significantly
different. Since multiple hypothesis test are being conducted, it is more appropriate
to use Bonferroni correction to help avoid false claims of a model being significantly
different.
Figure 2.1: Box plot representation of predictive AUC from 50-fold repeated hold
out trials
Figure 2.2: Box plot representation of predictive Brier score from 50-fold repeated
hold out trials
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Figure 2.3: Box plot representation of predictive F1 score from 50-fold repeated
hold out trials
GLM 1 GLM 2 CART 2 CART 3 Bag 3 RF 3 RF O3 MARS 1 MARS 2 Nnet 1 Bart 1
GLM 2 1 - - - - - - - - - -
CART 2 0.07634 0.03886 - - - - - - - - -
Cart 3 0.14185 0.07446 1 - - - - - - - -
Bag 3 1 1 0.00149 0.00326 - - - - - - -
RF 3 0.03543 0.06990 2.40E-09 7.63E-09 0.89933 - - - - - -
RF O3 0.02141 0.04321 1.00E-09 3.25E-09 0.61289 1 - - - - -
MARS 1 1 1 2.46E-06 6.58E-06 1 1 1 - - - -
MARS 2 0.92440 1 1.06E-06 2.90E-06 1 1 1 1 - - -
Nnet 1 1 1 0.29674 0.51577 1 0.00725 0.00417 0.43645 0.27391 - -
Bart 1 0.03346 0.06618 2.17E-09 6.92E-09 0.86112 1 1 1 1 0.00681 -
Bart 2 0.06792 0.12996 7.58E-09 2.35E-08 1 1 1 1 1 0.01485 1
Table 2.4: Pairwise t-test utilizing a Bonferroni correction term comparing out of
sample predictive Brier Scores
Our Bonferroni test confirms both the GLM and CART models are outperformed
by all other models. We then see the Nnet model is also outperformed by our top
models (BART 1, MARS 1, RF 3, and RF O3) based on an α level of .05 with
all three error measures (Note: RF O3 is the RF 3 model with oversampling). We
also notice there is no significant difference between our top models and our Bag 3
model with either error measure. However, Bag 3 performed slightly worse in the
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GLM 1 GLM 2 CART 2 CART 3 Bag 3 RF 3 RF O3 MARS 1 MARS 2 Nnet 1 Bart 1
GLM 2 1 - - - - - - - - - -
CART 2 0.5786 1 - - - - - - - - -
Cart 3 0.3183 0.81705 1 - - - - - - - -
Bag 3 1 1 1 1 - - - - - - -
RF 3 0.0000 0.00015 1 1 0.24380 - - - - - -
RF O3 0.0000 9.74E-05 1 1 0.18498 1 - - - - -
MARS 1 1 1 1 1 1 0.20795 0.15718 - - - -
MARS 2 0.4999 1 1 1 1 0.90635 0.71124 1 - - -
Nnet 1 0.0005 9.34E-05 6.75E-09 3.84E-09 5.14E-09 1.13E-17 5.79E+18 6.90E-09 3.49E-10 - -
Bart 1 0.0000 0.00018 1 1 0.28228 1 1 0.24127 1 1.62E-17 -
Bart 2 0.0002 0.00102 1 1 0.84991 1 1 0.73844 1 2.73E-16 1
Table 2.5: Pairwise t-test utilizing a Bonferroni correction term comparing out of
sample predictive AUC
GLM 1 GLM 2 CART 2 CART 3 Bag 3 RF 3 RF O3 MARS 1 MARS 2 Nnet 1 Bart 1
GLM 2 1 - - - - - - - - - -
CART 2 0.5786 1 - - - - - - - - -
Cart 3 0.3183 0.81705 1 - - - - - - - -
Bag 3 1 1 1 1 - - - - - - -
RF 3 0.0000 0.00015 1 1 0.24380 - - - - - -
RF O3 0.0000 9.74E-05 1 1 0.18498 1 - - - - -
MARS 1 1 1 1 1 1 0.20795 0.15718 - - - -
MARS 2 0.4999 1 1 1 1 0.90635 0.71124 1 - - -
Nnet 1 0.0005 9.34E-05 6.75E-09 3.84E-09 5.14E-09 1.13E-17 5.79E+18 6.90E-09 3.49E-10 - -
Bart 1 0.0000 0.00018 1 1 0.28228 1 1 0.24127 1 1.62E-17 -
Bart 2 0.0002 0.00102 1 1 0.84991 1 1 0.73844 1 2.73E-16 1
Table 2.6: Pairwise t-test utilizing a Bonferroni correction term comparing out of
sample predictive F1 scores
Brier score measure than the rest of our top models. We then tested these models
on our validation set to see which was better suited for prediction at UMRCC.
These prediction models output the probability a patient will defer or not show
for treatment on a given day. One application we have applied this to is in the
pharmacy at the UMRCC. If pharmacist are working to make ahead certain drugs,
information on patient deferrals ahead of time is crucial. When testing our models
on the validation set, we tested various decision thresholds (i.e. anyone below the
threshold would be assigned a value of 0 for treatment deferral/no show and anyone
above assigned a value of 1 for completed appointment).
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2.3.2 Selected Model Discussion
Model Brier score AUC F1 score
MARS 1 .11 .67 .88
BART 1 .1 .71 .78
RF 3 .1 .69 .77
RF O3 .11 .66 .72
Table 2.7: Final Model Performance Measures
Considering the results from our final comparisons seen in Table 2.7, BART 1 was
chosen as our final model based on slightly outperforming MARS 1 in both Brier score
and AUC as well as RF 3 and RF O3 in AUC and F1 score. Our prediction model
outputs a probability that a patient will complete their appointment. We then can
set a threshold to help us determine what the predicted response will be for a given
patient visit. Any predicted probability above the threshold will be classified as a
completed appointment and anything below as a deferred/no-show appointment. For
example, if we set a threshold at probability .75, we were able to correctly predict 21%
of deferrals/no shows and 93% of completed appointments with an overall prediction
accuracy of 84%. If we move the threshold from probability .75 to .8 we correctly
predicted 34% of deferrals/no shows and 79% of completed appointments with an
overall prediction accuracy of 82%. Depending on the applications, the decision
maker may favor predicting the positive outcome more accurately than the negative,
which in our case would favor the original threshold. Alternatively if predicting the
negative outcome accurately is more crucial than our increased threshold is favored.
Even if a decision maker is more favorable to a negative or positive response accuracy,
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use of optimization techniques to determine the optimal decision threshold has been
shown beneficial as done in [25]. In Figure 2.4 illustrates all tested thresholds.
Threshold 0.5 Threshold 0.55 Threshold 0.6
Accuracy 0.871 Accuracy 0.87 Accuracy 0.871
0 1 0 1 0 1
0 0 3 0 1 5 0 4 7
1 126 871 1 125 869 1 122 867
Threshold 0.65 Threshold 0.7 Threshold 0.75
Accuracy 0.861 Accuracy 0.852 Accuracy 0.844
0 1 0 1 0 1
0 8 21 0 17 39 0 27 57
1 118 853 1 109 835 1 99 817
Threshold 0.8 Threshold 0.85 Threshold 0.9
Accuracy 0.822 Accuracy 0.747 Accuracy 0.602
0 1 0 1 0 1
0 43 95 0 64 191 0 95 367


















































Figure 2.4: Confusion matrix for various thresholds for the top performing BART
model
2.4 Variable Significance
For purposes of interpretability, we first utilized the logistic regression model to
determine the significance of each variable in predicting patient deferral/no-show
status. Appointment Length, Previous number of visits, and Protocol ID have the
strongest positive influence on the response while previous number of cancelation
and number of days since last visit have the most significant negative effect on the
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response.
Next we tested the marginal effect of each covariate using the BART model.
Figure 2.5 consist of the partial dependence plots for all covariates and just a few
examples for our factors. Each x-axis represent the values taken by the variable being
tested and the y-axis represents either the probits or logits for each response. (The
higher the probit value the higher the probability of having a completed appointment.
This also holds for the logit scale in (i)) The blue lines illustrate the 95% confidence
interval for each dependence plot.
Based on the partial dependence plots, we see the number of previous
cancellations (c) and the number of days since the last visit (f) have the strongest
negative influence on the response (i.e. the higher the values the lower the probability
of completion). We also see that new patients and patients with at least 15 previous
visits have a higher probability of completing their appointment (e). We also give
examples of significant levels based on the logistic model for marital status and race
in (h) and (i). Lastly we note there does not seem to be a strong influence with age
(b) but there is a strong positive marginal effect with the days since last cancelation
on the probability of completing an appointment (d). Both appointment length (a)






Figure 2.5: Partial dependence plots for all covariates and some example levels of
the most influential factors used in our BART model
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2.5 Conclusion
This chapter highlights the potential benefits of using statistical models for
predicting patient deferrals in an outpatient infusion center. It not only presents a
variety of statistical prediction models, but also provides tools for comparing and then
selecting the most appropriate of these models for a specific clinical environment. We
found the BART model to have the best predictive performance, based on Brier score,
AUC, and F1 score, for the UMRCC outpatient infusion center. However, this may
not be true in other hospital settings. Our results suggest that, at least for our data
set, ensemble methods capable of handling non-linear data with interaction between
variables (e.g., BART and RF) provide stronger predictive accuracy than linear
models such a logistic regression. We hypothesize that this would generalize to data
from other cancer treatment centers. There are also trade-offs between predictive
accuracy and interpretability with some models being easier draw inferences about
variable importance and influence from than others but at the expense of predictive
accuracy. Because a cancer center is most likely to be focused on predictive accuracy
in practice, that has been our focus in this paper. However, each cancer center must
strike their own balance between interpretability and predictive accuracy. Similar
comparison procedures should be followed to determine the best prediction model for
each setting. We recognize with guidance from clinical collaborators our mo With
proper implementation, these models can enable clinicians and clinical managers to
achieve the in-practice benefits of deferral and no-show predictions.
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Chapter 3
Optimal Schedule for Pre-mixing Drugs
3.1 Introduction
In this chapter we propose to use Integer programming (IP) techniques to
determine the optimal set of drugs to make-ahead at an outpatient chemotherapy
infusion center given a finite window of time. IP models are widely used to address
scheduling and care delivery problems in healthcare such as scheduling elective
surgery patients, clinical providers, or pharmacy orders [26], [27], [28]. There are
also more specific research efforts focusing on scheduling of chemotherapy infusion
patients as discussed in [29], [30], and [31]. These methods ranged from complex
stochastic optimization models to more tractable and interpretable IP models in
excel. However, our specific problem domain regarding make-ahead drugs in a
pharmacy, specifically chemotherapy, is much more scarce in the literature. Currently
this problem has been addressed with queuing/simulation techniques and “Lean”
methods but not optimization [10] [32]. Another case study also The models in the
literature also disregard the predictability of patient deferrals and in turn miss the
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opportunity to utilize the probability of wasting a drug when determining which
drugs would be most advantageous to make ahead and when we should make
them. More broadly, pharmacy preparation improvements have been studied with
batched pharmacy orders [33] [34]. However, due to the highly personalized nature
of chemotherapy treatment, these methods are not generalizable to the outpatient
chemotherapy infusion center pharmacy domain.
In this chapter we focus on developing two tractable IP models that determine
the optimal number drugs to pre-mix. Given a finite amount of time for pre-mix,
we considered how to best use that time by maximizing the difference between the
value of expected reduced wait time and expected waste cost. This is done by
determining a monetary value for patient wait time as discussed in Section 3.2. We
utilize patients’ probability of treatment deferral determined in Chapter 2 to define
our expected waste cost and use the complement (i.e., the probability of completing
an appointment) to determine the expected reduced wait time. The first model
discussed in Section 3.3 assumes that all drugs being considered will last the entire
day since most drugs being considered for pre-mix have a shelf life/hang-by time of
at least 8 hours. Our second model discussed in Section 3.4, relaxes this assumption
to incorporate all drugs with any hang-by time. So depending on the specific time
a drug is made may not lend it viable to all the patients scheduled to receive it that
day. We note if multiple patients are scheduled to receive the same pre-mixed dose
and drug, then the drug labeling can be updated and given to any of the patients.
Both models consider the schedule of patients on a given day along with
their respective probability of treatment deferral. The model then balances the
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trade-off between potential reduced wait time and generated waste cost resulting
from pre-mixing a chemotherapy drug. In Section 3.2, we discuss how we directly
compared patient time with the potential waste cost associated with pre-mixing a
drug. After evaluating this trade-off, this model generates a schedule for pre-mixing
chemotherapy drugs to be utilized by a pharmacist.
3.2 Reduced Wait Time
One major challenge is how to define the expected value of reduced wait time
gained by pre-mixing a particular drug. Setting a dollar value for the reduced wait
time gained by pre-mixing a drug is a very controversial topic since we are trading
off the value of a patient’s time with a potential cost the hospital could incur. Some
studies define wait time cost as the average amount a person could have earned
working as their wait time cost [35]. Others define wait time cost by the hedonic
value of life as a set standard for patient wait time [36]. In our model we assume a
patient’s wait time is worth the average wage in the Detroit metro area, as reported
by the U.S. Bureau of Labor and Statistics, they could have made if working, which in
2017 was $25.22 [37]. Another aspect to consider when defining the value of reduced
wait time gained by pre-mixing a drug is the extent to which the opportunity cost
is the same for all infusion patients. Should sicker patients or patients with more
severe cancers have a higher cost associated with their wait time? Should the time
a patients spends away from their loved ones or home be considered? A range
of medical, interpersonal, and contextual factors exists in patients’ lives that are
difficult to quantify, but one must consider their role in defining the value of reduced
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wait time when pre-mixing a drug. We anticipate defining the cost for wait time to
continue to be a controversial subject so we plan to run a sensitivity analysis on this
wait time cost and leave it as an input for the decision maker. We also emphasize
the dollar value associated with reduced wait time is a constant value input to the
optimization models. This value can easily be scaled nonlinearly if for example the
decision maker found a subgroup of patients’ time was worth more then the general
population or if the decision maker considered 1 hour of reduced wait worth 2 times
the cost of 15 min of reduced wait time.
Additionally, our model takes a conservative approach when calculated the
expected wait time saved by pre-mixing a dose of a drug. While we only consider the
time it would have taken to mix a drug as the amount of reduced observed patient
waiting time, these time saving can also reduce the overall load on the pharmacy
system as a whole. (i.e., benefitting patients whose drugs were not pre-mixed). This
is discussed more when evaluating our simulation model in Chapter 4.
3.3 Chemotherapy Pre-mix Integer Program (CPIP)
As illustrated in Figure 1.2 from Chapter 1, the drug mixing process is complex.
However most steps take a trivial amount a time with the majority of the drug
processing time coming from the order verification steps taken before the drug is
made and the actual compounding time. We simplify our optimization model to
focus on these two steps which must still occur in sequence. For each drug, we input
the average verification time and compounding process time as input parameters.
While there is some variability here depending on the technician mixing the drug,
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it is not significant enough to implement a more complex stochastic model. Our
objective is to maximize the difference between the expected dollar value of reduced
wait time defined in Section 3.2 and the expected waste cost for mixing a drug given
a fixed window of time for pre-mix in the morning. We assume the following:
• The drug mixing times are deterministic
• We can predict the patient probability of deferral from a BART model as seen
in Chapter 2
• Pharmacy tasks can be reduced to two key steps (1) Drug Verification (2) Drug
Compounding (i.e., mixing)
• Drugs have a hang-by time lasting the entire day regardless of when the drug
was pre-mixed that morning
3.3.1 CPIP Formulation
We now present the IP model formulation for the CPIP model. We note the use
of time discretization in this model to allow us to use a simpler discrete model rather
than continuous time model. In the computational experiments, we further explore
at what granularity we should discretize time to balance solution quality with model
performance. The more granular the discretization, the more exact the solution.
Conversely, increased granularity also increases our problem size thus leading to
much longer solve times.
Sets
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• D: set of drugs d (e.g. 50 mg of Taxotere) Note: Each drug d represents a set
of patients scheduled to receive it.
• S: set of stages s (stage 1 verification; stage 2 drug compounding)
Parameters
• psd: the time duration for pre-mixing drug d in stage s ∀d ∈ D, s ∈ S
• ∆d: the product of the reward/value of reduced wait time for pre-mixing drug
d ∈ D and the value per unit of reduced wait time (i.e., (p1d + p2d)*patient time
value)
• T : the total time units for the pre-mix period
• T̄ ds = T − psd + 1: Most constraints only need to consider the last time slot a
drug can start being pre-made. We use T̄ to help simplify this notation for all
∀d ∈ D, s ∈ S.
• cd: the cost of drug d ∀d ∈ D
• md: the number of doses needed for drug d (i.e., the number of patients
scheduled to receive drug d) ∀d ∈ D
• Cs: total number of drugs you can mix at a time in stage s ∀s ∈ S
• Pd(n): the probability of wasting the nth dose of drug d, formally defined in
Section 3.3.2 ∀d ∈ D,n = 1...md
• M : very large number
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• Edn = ∆d(1− Pd(n)): The expected value of reduced saving when you pre-mix
dose n of drug d ∀d ∈ D,n = 1...md
• Edn = cdPd(n): The expected waste cost when you pre-mix dose n of drug d




1 if we start pre-mixing dose n ∈ {1...md} of drug d ∈ D at time t ∈ {1...T}








1 if we are pre-mixing dose n ∈ {1...md} of drug d ∈ D at time t ∈ {1...T}
for stage s ∈ {1, 2}
0 o.w.








(Edn[Reduced Wait]− Edn[Waste Cost]) ∗ xdnt1 (3.1)
Note we only need to consider a single stage when evaluating the objective since we
constrain our model to processing a drug through both phases if it is pre-mixed.
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Constraints
1. If you mix a dose of a drug, it must be done in both phases and can only be
started in each phase once for that dose n. If a particular dose n of drug d is





n = 1 ∀d ∈ D,n = 1...md, s ∈ S
2. If a dose of a drug is made then it must be processed a total of psd time units





d ∗ ydn = psd ∀d ∈ D,n = 1...md, s ∈ S
3. We must make the nth dose of drug d before the (n+ 1)th dose of drug d. If the
(n+ 1)th dose is not made, then the right hand side of our constraint takes on
the value of big M resulting in no restrictions on when we pre-mix the previous
dose. If a subsequent dose is made, ydn′ = 0 forcing the start of the subsequent






′xdn′t1 + M ∗ ydn′ ∀d ∈ D,n = 1...(md − 1) where n′ =
n+ 1
4. If you don’t make the nth dose you can’t make any subsequent doses (note:
n′ = n+ 1).
ydn ≤ ydn′ ∀d ∈ D,n = 1...(md − 1) where n′ = n+ 1
5. We can only make C drugs at a time at each stage s. Stage 1 capacity is driven
by the number of verification pharmacists on hand while stage 2 is limited by







nts ≤ Cs ∀t = 1...T, s ∈ S
6. Preemptions are not allowed once a drug starts the mixing process. We define
the index i to count from 0 to one less than the processing time for the given
drug d at stage s. This constrains our z variables to consecutively be 1 until a
drug is completed given we decide to pre-mix the drug starting at time t.
xdnts ≤ zdn(t+j)s ∀d ∈ D,n = 1...md, s ∈ S, t = 1...T̄ ds , j = 0...(psd − 1)
7. This constraint ensures each drug must complete Stage 1 before Stage 2. Since
we define our time unit at the beginning of the interval, the sum of when we
start a drug in Stage 1 plus the processing time for that drug in Stage 1 must









nt2 ∀d ∈ D,n = 1...md
3.3.2 Probability of Wasting a Drug: Homogeneous Patient Group
Utilizing the probability of wasting a drug has been shown to benefit pharmacy
operations in [38]. Now that we have formally defined our IP we must discuss
how the probability of wasting the nth dose of drug d, Pd(n), is formulated. We
note these probabilities are assumed to be independent between drugs and patient
probability of deferrals are also assumed independent from each other. Therefore
our formulation discussed in this section applies to each drug individually.
Wasting the nth dose
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We begin by assuming there is only one drug to be made, with m patients
scheduled to receive this drug. The first dose of the drug that is prepared will be
administered to the first patient of the day who does not defer, the second prepared
dose to the second patient who does not defer, and so forth. This is based on the
notion if a patient defers, then their drug can be used by any subsequent patient
since it is the same drug ordered for both patients.
Now suppose each patient has a probability p of being deferred or some other
reason not receiving their scheduled treatment. Given that the first dose made is
the first dose used, this dose will only be wasted if all patients defer. Therefore our
probability of wasting the first dose is given by







i.e., all patient must defer.
Now consider the case where we waste the second dose made. This can happen
either if we waste both the first and second dose (which happens if all patients defer)
or we use the first dose but waste the second dose (which happens if exactly one
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patient receives treatment and all others defer). This is given by the following:
















3.3.3 Probability of Wasting a Drug: Heterogenous Patient Group
Now we relax the assumption that all patients have the same probability of
deferral. We define the set S to contain the integers from 1 to m representing
all patients scheduled to receive the same drug on a given day. For example, given
m total patients scheduled for the day, S = 1, 2, 3, ...,m.
Similar to the homogeneous case, the probability of wasting the first dose given





the product of the probabilities of each patient deferring
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We waste the second dose if either everyone defers (i.e. the probability of wasting
the first dose) or if exactly one patient is well enough for treatment but the rest defer
resulting in only the first pre-made dose being utilized.

























We waste the third dose if all patients defer,(i.e., the probability of wasting the
first dose) or only one patient is well enough for treatment (i.e., the probability
of wasting the second dose), or exactly two patients are well enough and the rest
defer treatment (resulting in the first two doses being utilized but the third being
wasted.)
Summarizing, we see that:
A. Probability of wasting the 1st dose — all patients must defer treatment
B. Probability of wasting the 2nd dose — all patient must defer or only one is well
enough for treatment (i.e., Case A + Prob(one patient is well enough))
C. Probability of wasting the 3rd dose — all patient must defer, only one patient
is well enough for treatment, or only 2 patients are well enough for treatment
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(i.e., Case B + Prob(two patients are well enough))
Extending this logic, we observe, recursively, that the probability of wasting the
nth dose = Prob(wasting (n− 1)th dose) + Prob(n− 1 patients are well enough for
treatment).
To generalize this, suppose we have m patients scheduled to receive the same
drug on a given day. If we waste dose n then at most n − 1 people scheduled to
receive that drug can be well enough to receive treatment that day in order for the
nth dose to be wasted. Conversely, m− (n− 1) = m− n+ 1 patients must defer to
waste the nth dose of a drug. Considering this, we define sni as the i
th subset of S
which contains n − 1 patients who complete their appointment with the remaining
m − (n − 1) patients deferring treatment that day. Since we want to consider the
combinations of patients that need to defer out of the total m patients, we recognize





. (Ex. If we were considering the probability of wasting the third
dose with four total patients scheduled to receive that drug then |s3i | = 3− 1 = 2 ∀i.
s31 = {1, 2}, s32 = {1, 3}, ...). We note counting the negative cases of deferral is





























3.4 CPIP-Hang-by Time (CPIP-HT)
In CPIP from Section 3.3, we made the simplifying assumption that all drugs
lasted the entire day (i.e. had a hang-by time of at least 8-12 hours). Therefore no
matter what time they were pre-mixed in the morning, they would be viable for all
patients scheduled to receive that drug on a given day. In reality, some drugs have
shorter hang-by times (ranging from one to six hours). Therefore you must consider
when patients are scheduled for treatment when deciding which drug you decide to
pre-mix. Specifically, the probability of a particular dose of a drug being used (and,
conversely, of being wasted) depends on both the time that the dose is mixed and the
time of the patient appointments. Even more challenging, as we see in the following
example, it also depends on the time that other doses of the same drug are mixed.
Thus, we expand the original CPIP model to incorporate this additional problem
characteristic in CPIP-HT.
Example: Suppose we have two patients scheduled to receive the same drug,
with probabilities of deferral p1 and p2, respectively. In Figure 3.1a we illustrate a
timeline representing both the window of time to pre-mix and the scheduled time
for each patient (indicated with their probability of deferral). Figure 3.1b illustrates
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how pre-mixing a dose of in the beginning of our window results in that dose being
viable only for the first patient. This results in the probability of wasting the first
dose of the drug as p1. However in Figure 3.1c we show if the dose is made at the
end of the period it is viable for both patients. The probability of wasting the first
dose of the drug now becomes p1 ∗p2. This shows that the probability of wasting the
dose depends on the time it was made.
Now suppose we pre-mix two doses of this drug. In Figure 3.1d we consider the
case where both doses are viable for all patients hence the probability of wasting the
first and second dose follows the same formulation from Section 3.3.2 as
P (1) =p1 ∗ p2 (3.11)
P (2) =P (1) + (1− p1) ∗ p2 + (1− p2)p1. (3.12)
However if we make the first dose earlier in our pre-mix window, as we see in
Figure 3.1e, the first dose is now only viable for the first patient while the second is
viable for both. Therefore, the probability of wasting the first dose is simply p1, the
probability of wasting the second dose is given by








Figure 3.1: Example of eligibility windows: (a) Example of a timeline to represent
pre-mix window and two patients scheduled for the same drug (b) Here we show a
single dose of a drug pre-mixed and being eligible for a single patient (c) Here is
the same drug from the previous example but made at a later time to represent it
being eligible for both patients (d) Now we introduce two drugs both being eligible
for both patients (e) Illustrates two doses of the same drug being pre-mixed again
but the first being eligible for one patient and the second for both
This shows that the probability of wasting the second dose depends not only on
the time it was made, but also on the time that the first dose was made
3.4.1 Patient Eligibility Vectors
To determine the potential waste cost (and, in turn, the objective value)
associated with a particular dose of a given drug, we need to know when all the
doses of that drug were made. To accommodate this, first consider replacing the
simple variable xdnts, which determines whether the n
th dose of drug d was made at
time t in stage s, with a complex variable ydst1,t2...tm which determines whether you
made a particular set of doses for a given drug d at respective times t1, t2, ...tm in
stage s. (Note some ti’s are null if we do not pre-mix dose i.) This variable allows us
to fully capture the probability of deferral for each dose, and therefore the expected
cost of the associated drug. Unfortunately, this comes at the cost of an exponentially
large number of variables.
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Consider, however, the following example. Suppose we have three patients all
scheduled to receive the same drug. Depending on when you pre-mix a dose you
then could have from zero (i.e., you decided not to make the drug) to three total
patients eligible to receive the drug based on when they are scheduled for treatment




Figure 3.2: Example of eligibility windows: (a) Given 3 patients while pre-mixing
two drugs (b) Pre-mixing the same two drugs but a different times while keeping the
same outcome (c) The window of time where we can pre-mix these drugs to get the
same outcome
In Figure 3.2a we consider the case where we make 2 doses at times such that:
• for d1 - 1 patient is eligible
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• d2 - 3 patients are eligible
• d3 - 0 patients are eligible (not mixed)
Then in Figure 3.2b we consider making dose d1 earlier in our pre-mix window and
and d2 later but–observe that we still get the same outcome for patient eligibility!
Therefore in both cases, the expected waste cost will be the same. Further, as we
see in Figure 3.2c, any set of doses pre-mixed in the indicated windows of time will
yield the same probabilities of waste. We denote the bounds on these time windows
as time un and time ln for the upper and lower bound on when we can pre-mix
the nth dose of a drug which is further discussed in Section 3.4.4. No matter when
doses d1 and d2 were pre-mixed in this window, they would have the same associated
objective value for all combinations of our decision variable ydst1t2...tm . This examples
illustrates that we focus solely be on the number of patients eligible to receive a drug
(i.e. within the hang-by time window for each drug) rather than the time each dose
was made. We exploit this fact to reduce the size of CPIP-HT. Specifically, we define
a patient eligibility vector edi as the i
th collection of how many patients are eligible for
each dose of drug d along with the associated pre-mix time window [time ln, time un]
required for the vector to be feasible. Based on this definition, we now present the
CPIP-HT formulation.
3.4.2 CPIP-HT Formulation
Now that we have defined our patient eligibility vectors and the associated
pre-mix time window imposed by them, we present CPIP-HT. Our model follows
the same introduction as CPIP from Section 3.3 but relaxes that assumption all
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drugs have a hang-by time lasting the entire day. To determine our patient
eligibility vectors, we also assume patients arrive on time for their scheduled infusion
appointment (Note: the decision maker can incorporate a patient arrival tolerance
for a more conservative approach that account for tardiness)
We then define the full model as follows (Note: all new sets and parameters are
in bold):
Sets
• D: set of drugs d (e.g. 50 mg of Taxotere) Note: Drugs are defined by hang-by
time and the set of patients to receive that drug, along with their scheduled
time of appointments.
• S: set of stages s ∈ {1, 2}
• Ed: Set of eligibility vectors for all d ∈ D. The size of this set depends on
the number of doses scheduled for a given drug (eligibility vectors are further
discussed in Section 3.4.1)
Parameters We define all of our parameters for CPIP-HT as follows:
• psd: the time duration for processing drug d ∈ D in stage s ∈ S
• ∆d: the value for time savings of drug d ∈ D (i.e., (p1d +p2d)∗patient time value)
• T : the total time units for the pre-mix period
• T̄ ds = T − psd + 1 ∀d ∈ D, s ∈ S: Most constraints only need to consider the
last time slot a drug can start being pre-made. We use T̄ to help simplify this
notation.
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• cd: the cost of one dose of drug d ∈ D
• md: the number of doses needed for drug d ∈ D based on the number of
scheduled patients
• Cs: total number of drugs you can process at a time at stage s ∈ S
• δdi : total number of doses being mixed of drug d ∈ D if we choose eligibility
vector i ∈ E
• time udni: upper bound time unit on when dose n = 1...md of drug d ∈ D can
be made given eligibility vector i ∈ E is selected (Defined in Section 3.4.4)
• time ldni: lower bound time unit on when dose n = 1...md of drug d ∈ D can
be made given eligibility vector i ∈ E is selected (Defined in Section 3.4.4)
• M : very large number
• Edi [Waste Cost]: the expected wast cost associated with selecting eligibility
vector i ∈ E for drug d ∈ D (Defined in Section 3.4.3)
• Edi [Reduced Wait]: the expected reduced wait time associated with selecting
eligibility vector i ∈ E for drug d ∈ D(Defined in Section 3.4.3)






(Edi [Reduced Wait]− Edi [Waste Cost]) ∗ adi (3.14)
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Variables
We introduce a new variable a which allows us to select a patient eligibility
vector for each drug being considered for pre-mix.
• adi =

1 if we select patient eligibility vector i ∈ E for drug d ∈ D
0 o.w.
All variables from the CPIP model in Section 3.3 still hold.
Constraints
First we define our new constraints for CPIP-HT as follows:




i = 1 ∀d ∈ D
2. Here we ensure that the selected eligibility vector adi of drug d ∈ D has the
corresponding start pre-mixing time slot assigned for all doses δdi determined
by the eligibility vector i ∈ E. For example, if we selected an eligibility vector





t4 set to 1 in exactly one of our t time slots while x
d












i ∀d ∈ D
3. The nth dose of drug d must be started in phase 2 before the upper time limit
to ensure it wont expire before all eligible patients are scheduled to receive that
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drug from our selected eligibility vector i. We further discuss how this time









i ∀d ∈ D,n = 1...md
4. Drugs must be started in phase 2 after the lower time limit to ensure it
wont expire before all eligible patients are scheduled to receive that drug from
our selected eligibility vector i. We further discuss how this time bound is









i ∀d ∈ D,n = 1...md
Once a vector is selected we still utilize the CPIP constraints from Section 3.3.1
Next we further define some parameters from Section 3.4.2.
3.4.3 Probability of Waste, Expected Waste, and Expected Savings
Definitions
The CPIP-HT model described in Section 3.4.2 requires us to calculate P (n, i),
the probability of wasting the nth dose of a drug given an associated patient eligibility
vector i. These probabilities, which also depend on the number of patients eligible
for doses 1 through n− 1, are in turn used to compute the expected waste cost and
value of reduced wait time.
To derive P (n, i), we begin by considering the probability of wasting the first dose
of a drug, given patient eligibility vector ei. Note that this dose will be used so long
as at least one patient within the hang-by time window of that dose is well enough
for treatment; conversely, it is only wasted if all of the patients eligible for that dose
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defer treatment. Recall that, given a patient eligibility vector ei = [w1, w2, ..., wm]
where wn is the number of patients eligible to receive the n
th dose of that drug. We
also note that any patient in the window of eligibility for dose n is also in the window
for eligibility for all subsequent doses.
We first consider the probability of P (1, i), i.e., wasting the first dose made under
eligibility vector ei. We can compute P(1,i) as the product of the probabilities of




We next consider the probability P (2, i) of wasting the second dose given patient
eligibility vector i. This can happen in one of two ways – either none of the patients
in {1...w2} (i.e., patients eligible to receive the second dose ) receive treatment or
only one patient from {1...w2} receives treatment, and this patient must also be
eligible to receive the first dose and therefore be in set {1...w1} (i.e., there is only
one patient being treated, and they receive the first dose). This can be expressed as




plus the second term is comprised of all combinations of the probability one patient is
well enough for treatment that is also eligible for the first dose times the probability
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Similarly, the probability P (3, i) of wasting the third dose given patient eligibility




all combinations of only one patient receives treatment and that patient is also eligible
to receive the second dose of the drug (which includes all patients eligible to receive







or all combinations of all but two patient receive treatment where both of these









To define this in a general sense, we recognize that if there are k < n patients
who receive treatment and the nth dose is wasted, then at least k patients must be
eligible for the dose n− 1, at least k − 1 of these must be eligible for dose n− 2,...,
and at least 1 of these patients must be eligible for dose n−k. We define the set sinkj
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as the jth subset of patients associated with patient eligibility vector i such that:
• ≥ k of the patients are in {1...wn−1}
• ≥ k − 1 of the patients are in {1...wn−2}
• ≥ k − 2 of the patients are in {1...wn−3}
...
• ≥ 1 of the patients are in {1...wn−k}
We then define Sink as a set containing all j subsets s
i






patient eligibility vectors i and k < n. We now can generalize P (n, i) as follows:
for n = 1




for n > 1

















Expected Waste and Savings
Now that we have defined the probability of wasting the nth dose of a drug given
the patient eligibility vector ei and md total patients, we can expand this to consider
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multiple drugs and define our expected waste and value of reduced wait per unit of
time as










where ∆d is defined in Section 3.4.2
(3.25)
where (1− Pd(n, i)) = 0 and Pd(n, i) = 0 for all doses n not pre-mixed given patient
eligibility vector ei. We recall ∆d as the dollar value place on a unit of reduced
patient waiting time. This value is a function of how long the drug takes to mix
which is the minimum time a patient would need to wait for the drug. We also recall
md as the total number of doses (patients) scheduled for a given drug d.
3.4.4 Calculating Pre-mix Windows
To determine the time window when each dose must be pre-mixed given patient
eligibility vector i, we first define some additional terminology and notation:
• T : the total time units we have to pre-mix drugs (e.g., discretizing the time
units by 5 minute increments with a two-hour to pre-mix period yields T = 24)
• prepd: total time is takes to prepare drug d ∈ D (i.e., the processing time in
both stages p1d + p
2
d
• hangbyd: hang-by time for drug d ∈ D (i.e., how long the pharmacy has to
administer the drug after it is mixed) in time units
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• sch timend : the number of time units from the end of the pre-mix window
until the patient scheduled to receive the nth dose of drug d ∈ D is ready for
treatment for n = 1...md (e.g., given a patient scheduled to receive the first
dose of drug d at noon with infusion appointments starting at 8:00am, then
sch time1d = 4 hours ∗60 min/hour ∗15 units/min = 48)
• tnd: the time we start mixing the nth dose of drug d ∈ D for n = 1...md
• storage time: the time a drug is stored after being pre-mixed before the infusion
appointments start. (e.g., if a drug is finished being mixed 1 hour into the
two-hour pre-mix period, the storage time will be 1 hour as well.)
• edi: patient eligibility vector i ∈ Ed given drug d ∈ D
• time udni: upper bound time unit on when dose n = 1...md of drug d ∈ D can
be made given eligibility vector i ∈ E is selected
• time ldni: lower bound time unit on when dose n = 1...md of drug d ∈ D can
be made given eligibility vector i ∈ E is selected
Using this notation, for a given dose n of drug d we then calculate:
1. Complete preparation time of each dose
2. Storage time of each pre-mixed dose
3. Determine how much life a drug has left based on when it was pre-mixed before
patients arrived
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4. Upper and lower time limits on when a dose can be pre-mixed given patient
eligibility vector i ∈ Ed ∀d ∈ D
Suppose we start preparing dose n of a given drug d at tnd. Then we will complete
preparing the dose at time tnd + prepd − 1. (Note we define our time units at the
start of the unit. So a drug that takes 4 units starting at t=1 will be mixed until
t=4). The storage time will then be
T − (tnd + prepd − 1) ∀d ∈ D,n = 1...md (3.26)
Given hangbyd as the time until drug d must be administered, the latest time a
patient can be scheduled and still receive it is the hang-by time minus the storage
time (e.g., if a drug has an 8 hour hang-by time and is finished pre-mixing 30 minutes
into the 2 hour pre-mix window, then there will be an adjusted hang-by time set to
6.5 hours). This is expressed as
hangbyd − (T − (tnd + prepd − 1)) ∀d ∈ D,n = 1...md. (3.27)
Now we can define our pre-mix windows introduced in Section 3.4.1. Referring to
Figure 3.2c we see that a drug must be pre-mixed late enough that is it viable for
the correct number of patients associated with eligibility vector i, but it also must
be mixed early enough to not be eligible for any later patients. In our example
with three patients, to determine the time windows for the patient eligibility vector
edi = [1 3 0] we need to ensure the first dose is made late enough to be eligible for the
first patient but early enough that it is not eligible for the second or third patient.
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We define the upper and lower pre-mix window limits for all doses in patient
eligibility vector edi as follows
time ldn =sch time
d
n=edij
− hangbyd + T − prepd + 1 ∀d ∈ D, j, n = 1...md, i ∈ E
(3.28)
time udn =sch time
d
n=edij+1
− 1− hangbyd + T − prepd + 1 ∀d ∈ D, j, n = 1...md, i ∈ E
(3.29)
where edij and e
di
j+1 are the j and j + 1 element in e
di (e.g., in our example edi1 = 1
and edi2 = 3) (Note: for any time u
d
n > T we determine that vector as infeasible)
3.4.5 Generating Patient Eligibility Vectors
Recall the ith patient eligibility vector edi (also referred to as just an eligibility
vector) associated with a drug d has one element j for each dose n of drug d (i.e.,
|edi| = md). edi specifies the number of patients eligible to receive dose n (with edij = 0
if dose j was not pre-mixed). Associated with that, as described in Section 3.4.4, is a
time window [time ldn, time u
d
n] such that, if dose n is pre-mixed at any time within
that time window, the number of eligible patient will be exactly edin . Also recall that
by definition, we make the first dose of a drug before the second dose and so forth.
Similarly, if we don’t make the nth dose then we don’t make any future (n + 1)th
doses either for all n. Finally, because the doses are all pre-mixed prior to the arrival
of the first patient, then edij+1 ≥ edij , except for doses that are not pre-mixed (i.e., any
patient eligible to receive the nth dose will also be eligible for the (n+ 1)th dose.
Consider, for example, eligibility vector [1 3 4 0]. The cardinality of this vector is
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four, meaning we have four patients receiving this drug and therefore four potential
doses to pre-mix. edi1 = 1, meaning that the first dose must be mixed late enough
to still be viable for the first patient, but early enough that is expires before the
treatment time of the second patient. edi2 = 3, meaning that the second dose must be
pre-mixed late enough to still be viable for the first three patients, but early enough
that it expires before the treatment time of the fourth patient. edi3 = 3, meaning that
the third dose must be mixed late enough to be viable for all four patients. edi4 = 0,
meaning the fourth dose is not pre-mixed in this vector i. Given an eligibility vector,
we then can determine the expected waste cost and expected reduced wait time
associated with it as described earlier.
To determine the total number of eligibility vectors for each drug, we rely on a
data structure called a multiset [39]. Formally a multiset A is defined as
A = {am(a1)1 , ..., am(a1)n } (3.30)
where an is the n
th unique element in the set and m is a function expressing the
multiplicity of that element. One example of a multiset is expressing the prime
factors of a number. For example 100 = 2252 which results in the multiset {2, 2, 5, 5}.
In this example a1 = 2, a2 = 5,m(a1) = 2, and m(a2) = 2. Unlike a set, in which
each element must be unique, a multi-set can repeat elements. However, as in a set,
the order does not matter, i.e. {3, 4, 4} and {4, 3, 4} are the same multiset. Thus we
can think of our eligibility vectors as multi-sets, and use the associated properties to
count the number of potential eligibility vectors.
When counting a multiset, we define q as the cardinality of an individual multiset
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and define r as the cardinality of the finite set that all of the elements of our
multiset are taken from (i.e., the number of options for each element in the multiset).
Therefore, the number of multisets of cardinality q with elements taken from a finite
set r is given by
g(q, r) =
(




[40] In our problem context, q is the size of the eligibility vector m, (i.e., the number
of doses to potentially be pre-mixed). Each element of the vector (the number of
patients eligible for that dose) can be from 0 to m, with 0 representing the decision
to not pre-mix. Thus r = m+1 resulting in us counting the number of combinations







Given that Equation 3.32 is the total number of eligibility vectors for a given drug,
we can then sum over all drugs d to get the total number of eligibility vectors (and








Table 3.1 illustrates how these values grow. However, we can also exclude
eligibility vectors for which the jth element of the vector is less than j since they
are sub optimal (e.g., [1 1 0 0] would be suboptimal since there is no value in
pre-mixing two drugs that will only be viable for the same single patient). Table 3.1











200 1 400 400 0
100 2 600 500 100
50 4 3500 2450 1050
25 8 321750 7940 313810
20 10 3695120 2225320 1469800
Table 3.1: Growth of the upper bounds on the number of pre-mix vectors given
the total number of drugs and doses on a given day, we emphasizes this table starts
with the most likely case to very rare instances of our problem
3.5 Computational Experiments
In this section we analyze the performance, tractability, and solution quality of
our IP models from Section 3.3 and Section 3.4. We seek to answer the following
questions:
• How large is our problem (i.e., number of variables and constraints)?
• What is the computational time to generate the model inputs and solve the
model?
• How granular do we need to discretize time to still have a quality solution?
• How sensitive are the solutions based on the decision makers’ value of wait
time?
To run these experiments and address these questions, we use a Windows server with
two Intel Xeon E5-2620 8-core processors running at 2.10-GHz with hyper-threading
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and 128 GBs of RAM. The model was run with the IBM ILOG CPLEX Optimizer
(version 12.8.0) Python API package.
3.5.1 Input Data Sources
We utilize data from the pharmacy’s system, DoseEdge, to determine mixing
time ranges and drug order quantity/frequency, as well as MiChart data to generate
a sample patient schedule used in our experiments. Our collaborators from UMRCC
also provided us all drug costs to the pharmacy, drug hang-by times, as well as the
pharmacy capacity (e.g., number of compounding hoods and maximum number of
pharmacists scheduled at one time). While the probability of deferral for patients
varies in our experiments, all cases utilized data further discussed in Chapter 2.
3.5.2 Design of Experiments
To address these questions, we test three scenarios:
1. at most 1 dose of a drug is scheduled
2. 2-5 doses of each drug are scheduled
3. 10 doses of each drug are scheduled with 2 doses of one additional drug
We use a drug order schedule based on a single day with 122 patients scheduled
for chemotherapy infusion treatment with a fixed two hour pre-mix window. All
experiments have a fixed capacity based on three pharmacists and six technicians on
the schedule during the pre-mix period (i.e., there is capacity to verify three drugs
and compound six drugs at a time) to mimic the actual pre-mix window staffing
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schedule. We also incorporate variable mixing times for each drug and verification in
all of our experiments since some orders are more complex than others. In the first
set of experiments we discretized time into five, two, of one minute increments. For
example, given a drug that takes 23 minutes to mix, using five minute granularity
would result in the drug reserving 25 minutes to mix, two minutes granularity would
be 24 minutes and one minute granularity would be the true time of 23 minutes (i.e.,
we round up to the nearest discretized minute). While this drug’s mixing time varies
by the granularity of the discretization, pre-mixing this drug in all time varied cases
results in 23 minutes of saved wait time.
For all three scenarios in each time discretization, 10 instances of the problem were
generated and solved. These instances varied only by which drugs were randomly
generated to be scheduled for use on the given day. We report the median, maximum,
and minimum result of those 10 instances for each scenario. In Section 3.5.3 we
address our problem size and performance questions. In Section 3.5.4, we determine
the best time discretization granularity level. Lastly, Section 3.5.5 addresses how
sensitive our model is to the decision makers value on reduced patient wait time. We
note all models were solved with a two hour solve time limit as well as a 1% relative
optimality gap limit.
3.5.3 Models Performance and Tractability
Table 3.2 highlights how much larger CPIP-HT is compared to the CPIP model
in all discretized time cases. Additionally, as we increase the granularity of our time
discretization for both models the problem increases in size. However, referring to
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Table 3.3 we see the solve time between CPIP and CPIP-HT is not significantly
different until we get to the one minute granularity case where CPIP-HT solves most
instances of the problem significantly faster. However, having to generate such a
large number of input parameters (i.e. patient eligibility vectors) in the CPIP-HT
model, the load time is significantly longer for scenario 3 resulting in CPIP-HT
actually performing slower in most instances based on total load plus solve time.
We note both models follow the trend that increasing the granularity of the time







CPIP 5 min 1 10876 20688
2 10905 21076
3 10906 21642
2 min 1 26806 113939
2 26913 115085
3 26875 118970
1 min 1 53379 437824
2 53580 442860
3 53514 457218
CPIP-HT 5 min 1 11118 20930
2 11351 21207
3 1377780 21668
2 min 1 27048 114181
2 27358 115191
3 1393749 118996
1 min 1 53621 438066
2 54061 442966
3 1420388 457244
Table 3.2: Total number of variables and constraints for all scenarios of all time
discretization cases for the CPIP model and the CPIP-HT model
67
Load Time (sec) Solve Time (sec)
Model Case Scenario Median Min Max Median Min Max
CPIP 5 min 1 2.0 1.9 2.0 5.7 4.3 9.5
2 1.8 1.7 1.9 12.0 3.4 26.4
3 1.7 1.6 1.7 7.7 4.4 14.4
2 min 1 6.3 6.1 6.6 31.9 22.1 254.1
2 6.3 6.0 6.6 432.0 40.5 1290.0
3 6.4 6.1 6.6 54.3 29.7 722.9
1 min 1 21.1 20.0 22.0 2029.7 261.4 7200
2 21.1 20.5 22.6 6982.7 2323.2 7200
3 21.8 20.7 22.5 1568.6 275.8 6514.8
CPIP-HT 5 min 1 1.7 1.6 5.1 5.9 4.1 11.6
2 1.6 1.4 1.8 10.1 5.1 18.1
3 6632.4 6607.6 6638.0 85.1 77.2 93.6
2 min 1 6.3 5.8 10.0 54.3 24.1 593.3
2 6.3 6.0 6.5 446.4 53.0 1270.1
3 7097.8 7069.5 7102.6 126.4 92.3 161.3
1 min 1 20.4 19.4 25.5 3238.4 206.2 4933.1
2 20.3 19.3 21.5 3200.3 340.6 7200
3 6628.4 6597.6 6643.1 308.6 145.7 1681.0
Table 3.3: Summary table of model load and solve time for all instances in all
scenarios for our variable drug cases
CPIP-HT’s superior solve time in scenario 3 is partly attributed to the model
pre-solve. Referring back to our time bounds in Equation 3.3, there are some
instances of the dataset which cause the upper and lower time bound to be outside of
our pre-mix window. This results in an infeasible patient eligibility vector which can
quickly be discarded during pre-solve. For example, suppose we have an eligibility
vector [1, 3, 3] associated with a drug with a three hour hang-by time. The time
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bounds on this vector would be feasible if one patient was scheduled right when
infusion opened then the other three receiving the same drug were scheduled an
hour later. However, if these patients were scheduled hours apart, it would not be
possible to pre-mix three doses of the same drug and have the first dose only be
viable for the first patient and the next two doses viable for all patients.
3.5.4 Solution Characteristics
Next we compare the objective values between all scenarios of the five, two, and
one minute discretization cases with both CPIP and CPIP-HT models. In Figure 3.3a
and 3.3b, we notice the objective values increase between scenarios 1 and 2. However,
the objective value in scenario 3 decreases back to the objective value of scenario 1
or lower. While about 46-54 drugs were pre-mixed in both models for all granularity
levels, only 36-38 drugs were pre-mixed in scenario 3. Although fewer drugs were
pre-mixed, the pre-mixed drugs had the highest median preparation time across all
instances of the problem resulting in a higher expected saved waiting time.
While not significant, there is a difference between the CPIP and CPIP-HT
objective values since the later incorporates hang-by time reducing the number of
feasible solutions in our CPIP-HT model.
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(a) Objective values across all instances for each scenario in the
CPIP Model
(b) Objective values across all instances for each scenario in
the CPIP-HT Model
Figure 3.3: Objective Value for all instances and scenarios
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From these results we observe there is no significant difference between the
solution quality of the 2 min time granularity case with this 1 min case. However,
there is a significant increase in both load and solve time when moving from 2
minute to 1 minute granularity. Therefore we continue using discretized time units
of 2 minutes for the rest of our analysis.
Figure 3.4: Number of drugs pre-mixed by hang-by time in the 2 min variable time
drug case
3.5.5 Wait Time Value Test
Next we show how varying the value of patient wait will affect the model
solution. We increment our reward by $10 from $0-$100 then by increments of
$100 from $100-$1000 and observed how the number of pre-mixed drugs and their
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characteristics changed as we increase this value. We note since our models reached
optimality well within our two hour limit, we reduced the solve time limit to 1 hour
to run all 10 instances for each reward value in a reasonable amount of time. As
mentioned in the previous section, analysis was conducted discretizing time units to
two minutes.
Figure 3.5: Average, minimum, and maximum median drug cost for all pre-mixed
drugs as we increase the value of patient wait time (Note the max med cost is scaled
by 100)
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Figure 3.6: Total number of drugs pre-mixed as we increase the value of reduced
wait time
Figure 3.7: Total number of drugs pre-mixed grouped by hang-by time
We notice in each figure after our reward (i.e., valued on a patients reduced wait
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time) reaches about $200, our solutions stabilize. While in Figures 3.5 and 3.6 we do
see a significant increase in the median cost of all drugs and the median number of
drugs pre-mixed as we increase the reward value, respectively. However in Figure 3.7,
there is not as significant change in the hang-by time distribution of the drugs.
3.5.6 Summary
In Section 3.5, we test the CPIP and CPIP-HT model on 10 instances of three
scenarios with various time discretization levels of our problem. We determined
discretizing to 2 minutes is sufficient to maintain a good tradeoff between quality
solutions and model run-time performance. We also demonstrate in some cases the
CPIP-HT model reaches a more accurate solution in less computational time than
the CPIP model. This can be due to many things such as the CPIP-HT model is
able to eliminate many variables in the pre-solve due to some eligibility vectors being
infeasible. Additionally, since our decision variable defines a series of doses to pre-mix
rather than single doses, this potentially eliminates some fractional solutions which
would lead to infeasible integer solutions. We also demonstrated how our decision
maker might evaluate their value on patient wait time and how that affects the
CPIP-HT model solutions.
3.6 Conclusion
In this chapter, we developed two IP models to help determine the optimal set of
drugs an outpatient chemotherapy infusion center pharmacy should pre-mix, given a
finite amount of time. By pre-mixing chemotherapy drugs before patients arrive, the
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infusion center reduces the amount of time patients need to wait for their drugs to
be prepared and, in turn, decreases the load on the system during peak hours in the
pharmacy. Additionally, our model minimizes the projected waste cost associated
with pre-mixing this set of drugs.
To do so, we first incorporated patients’ probability of treatment deferrals from
Chapter 2 to determine the probability of wasting a dose of a drug given it was
pre-mixed with a pre-determined number of patients eligible to receive it. We
developed two probability functions. The first assumes all drugs remain viable the
entire day after they are mixed. The second version relaxes this assumption by
addressing the time dependence between doses when considering hang-by time (i.e.,
the probability of wasting the nth dose of a drug depends on how many patients were
eligible to receive that dose as well as when all prior doses were made). Both of these
functions were directly incorporated in our CPIP and CPIP-HT models, respectively,
to determine the expected waste cost and value of reduced wait time associated with
pre-mixing a set of doses of various drugs.
In our computational experiments, we compared various scenarios between the
CPIP and CPIP-HT models. While CPIP-HT run time was significantly higher,
it still remains tractable and is the more accurate model since it incorporates drug
hang-by time. Through our experiments, we show an optimal set of drugs for pre-mix
can be found in a timely manner while minimizing waste cost and maximizing the
value of reduce wait time of a patient. We also empirically showed the point at which
a decision maker’s value on wait time no longer affects the IP solution.
As future work, we look to expand how we define the value of reduced wait
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time. Currently all doses of the same drug have the same value of reduced wait as
it is only dependent on the time it takes to prepare the drug in the pharmacy.
However in Chapter 4, we show that pre-mixing drugs for patients strategically
spaced throughout the schedule is more beneficial then pre-mixing for the first few
patients in the morning. To address this, we suggest introducing a time-dependent
reward. Consequently, the value of reduced wait for a dose of a drug being pre-mixed
for a patient scheduled during peak hours would be higher than another dose of the
same drug being pre-mixed for a patient schedule during off-peak hours.
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Chapter 4
Modeling the Impact of Pre-mix Policies through
Discrete-Event Simulation of the Pharmacy
4.1 Introduction
Healthcare operations, care delivery, and treatment decision making are just a few
examples where data-driven modeling has greatly impacted performance and grown
in popularity as data access has improved [41]. Discrete-event simulation stands as
one of the most tractable methods practiced to improve overall healthcare system
performance [42], [43], [44], [45]. This increasing trend of performance improvement
models exists for cancer treatment centers as well [46], [47].
Cancer patients who require chemotherapy infusion undergo exhausting and
lengthy infusion sessions over the course of their treatment. These session lengths
can increase even more during peak demand hours due to delays in the pharmacy.
Through observations of work flow and interviews with pharmacists at UMRCC,
we determined peak drug demand hours on certain days of the week. During
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these peak hours, the pharmacy can get backed up to the point of taking up to
two hours to get a drug out to a patient. Therefore, one major opportunity to
reduce patient delays is by optimizing drug preparation at the pharmacy. Drugs can
be prepared (i.e., compounded) ahead of time to prevent patients from waiting as
their chemotherapy drug(s) is/are compounded as done in [10]. However, patients
scheduled for outpatient chemotherapy infusion may be deferred for treatment (i.e.,
last minute cancellation due to not meeting medical parameters or personal reasons
such as a family member not being available to support the patient) after arriving
for their appointment [11]. Consequently, the infusion center may incur a waste cost
if a drug is made ahead and the patient defers treatment. Infusion centers must
implement policies, determining which drugs to make before patients arrive given
a fixed window of time, to balance this potential waste cost with the time savings
for their patients and staff. In support of this effort, we developed a discrete-event
simulation, using UMRCC data, that has widespread applicability to evaluate the
effectiveness of pre-mixing chemotherapy drugs as well as the drug planning process
in general. This simulation allows us to take multiple sets of drugs determined for
pre-mix, along with the patient schedule for the day, and simulate the performance
(i.e., time in system and staff utilization) of these sets (i.e., compare the pre-mix
policies). Through our computational experiments, we test proposed methods to
create pre-mix policies. For example, if a drug is below a certain cost threshold
and one or more patients are scheduled to receive it below a certain probability of
deferral, then we can pre-mix the drug. We incorporate patient deferral probabilities
from the prediction model in Chapter 2. The simulation allows us to test various
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make-ahead policies for mixing drugs throughout the day. Improvements made at
the pharmacy may reduce patient delays and nurse overtime in the infusion area. We
propose various policies ranging in risk tolerance. More conservative policies mimic
the current state of pre-mix which are solely cost based. Conversely, less conservative
policies consider pre-mixing higher-cost drugs if the probability of wasting them is
low enough. Although all policies save time, the purpose of the simulation is to
determine how much time and whose time (patient or pharmacist/tech).
As previously mentioned we use a discrete-event simulation model to predict the
effectiveness of various make-ahead drug policies and validate this model using a case
study based on data from the UMRCC. The expected wait time for premixing a drug
is determined by the known preparation time of the drug. In 3, we introduced the
formulation for an expected saved wait time for a patient if their drug is pre-mixed.
This expectation is based on an assumed distribution for the mixing time of that
patients drug. This also assumes that the pharmacy is running smoothly and
never gets backed up during the day. Through observations and interviews with
pharmacists at UMRCC, we know there are peak drug demand hours on certain
days of the week. During these peak hours, the pharmacy can get backed up to the
point it takes up to two hours to get a drug out to a patient. We then utilize the
discrete event simulation to relax this assumption and to better predict the affect of
pre-mixing on the entire system rather than for the specified patient.
Next we will use the simulation to test various policies for mixing drugs
throughout the day. Discrete simulation will also let us test multiple objectives
such as nurse utilization, chair utilization, patient waiting time, and unit closing
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time as done in [48]. Instead of just considering the drug cost for various policies as
done in [10], we also introduce how to incorporate the patient deferral probabilities
from our prediction model in Chapter 2. For example, if a drug is below a certain
cost and two or more patients are scheduled to receive it below a certain probability
of deferral then we can premix the drug. We then want to explore the pharmacy
interaction with other areas in the cancer center (i.e. model the entire network).
Improvements made at the pharmacy may reduce patient delays and nurse overtime
in the infusion area. Discrete simulation has been used in other outpatients cancer
centers with similar objectives [46], [47]. The rest of this section is structured
as follows: Section 4.2 defines the problem we are solving, Section 4.3 describes
the simulation modeling construction and all assumptions, Section 4.4 presents our
computational experiments, and Section 4.4.4 provides discussion and conclusion.
4.2 Problem Description
The drug mixing process at the pharmacy consists of a series of order verifications,
the actual compounding of the drug, and safety checks to ensure safe delivery to
patients. The process we model begins when a drug order has been received by
the pharmacy (i.e., the patient has arrived at infusion and is ready to be treated).
Figure 4.1 illustrates the various steps taken and various checks needed to complete a
chemotherapy drug order. If a drug is pre-mixed, all steps are performed in advance
except for the final safety check. The drug mixing process is carried out by various
pharmacist and technical staff. Pharmacists conduct both the order verification and
safety check of all drugs. They are assigned to one of these two tasks for the first half
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of the day then switch. Pharmacy technical staff serve one of two roles: compounding
drugs under the hood or printing all labels and collecting supplies.
Figure 4.1: Pharmacy process flow for chemotherapy infusion drug orders
For simulation purposes, we simplified this process flow into five main steps.
1. Check if the drug was made ahead (pre-mixed), if yes skip to Step 5 otherwise
continue to Step 2.
2. Complete two drug verifications; must be done by two different pharmacists
3. Print labels and collect supplies for the drug order
4. Compound the drug and perform the first safety check. If order is mixed
incorrectly, the same tech must remake the order (i.e. repeat Step 4)
5. Perform the safety check and deliver the completed order.
Arrivals are determined based on the patients’ appointment time plus some
random deviation where a negative deviation means the patient was early and
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positive means they were late. Each time a new order arrives, the orders are sorted
first by arrival time then by appointment time (i.e., if two orders arrive at the same
time before the pharmacy opens, the order with the earlier appointment time will
be processed first). Orders are then released to follow the process in Figure 4.1.
Once a drug is verified twice (Step 2) and all supplies have been gathered (Step 3),
it then can proceed to the mixing hood. After the drug is mixed, the remote safety
check is performed by the pharmacist. Before compounding the drugs, the mixing
tech must take a photo of all materials and another photo after the drug has been
fully compounded. The safety check pharmacist must review these images before the
mixing process can be marked as complete. However, during this check, the mixing
tech cannot conduct any other work. Since the historical data is only captured when
a drug entered and exited the mixing hood, we included this initial safety check in
the mixing time for our drugs. We note this safety check is performed in addition to
the final safety check/drug delivery in step 5 of our simulation. Refer to Appendix C
for more detailed simulation logic.
4.3 Simulation Model
Our simulation was built using the SimPy module in Python version 3.6. The
model is initiated with a set of orders scheduled for the day, with some being flagged
as pre-mixed, each of which has a scheduled arrival time for the corresponding
patient. The actual arrival time of orders, the length of each service, and the potential
for the compounding service to fail are all stochastic. Due to the interest of our
collaborators, variable staffing was outside the scope of this project. Our metrics
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are the time in system for each order (i.e., perceived patient wait time) and the
utilization of all resources (i.e., pharmacist and techs at the pharmacy).
4.3.1 Input Parameters
Our simulation input parameters are determined using a combination of
observations, historical data, and expert pharmacist opinion. Using the Scipy module
in Python, we fit all distributions used for arrival time and service time estimation
as seen in Table 4.1.
Process Distribution Description
Patient Arrivals JohnsonSU (-0.428,1.41,-2.767,45.511) Negative values=early arrival Positive=late arrival
First Verification Triangular (1,2,15) Expert Opinion in min
Second Verification Triangular (1,2,5) Expert Opinion in min
Print Labels/Kit Triangular (1,3,5) Expert Opinion in min
Drug Mix Time Beta (1.461, 1376723443.471, 1.019, 7036129537.303) Historical Data
Safety Check Pearson3(2.509, 3.583, 3.240) Historical Data
Table 4.1: All input distribution and parameters used in our simulation model
While the arrivals are appointment driven, most patients’ actual arrival time will
deviate from their scheduled appointment time due to the stochastic nature of any
previous appointments as well as general tardiness or earliness. An additional delay
can occur since a pharmacy order is only initiated once a patient has arrived and
checked-in for their infusion appointment. We approach modeling the arrival process
by first determining the distribution of the deviation from scheduled appointment
time to actual arrival time (check-in time) similar to [49] [50]. Figure 4.2 presents a
histogram of the arrival deviation data along with the JohnsonSU distribution used
for arrival estimations in the simulation similar to [44].
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Figure 4.2: JohnsonSU Arrival Deviation Distribution Fit based on historical data
taken from UMRCC MiChart (Epic Product) Medical Records from 2016
The model also incorporates patients deferrals/no-shows. From the pharmacy
perspective, this will only affect the metrics if a patient’s drug is pre-mixed and
they have a same day deferral/no-show. To determine this probability, we trained
a Bayesian Additive Regression Tree (BART) model with demographic (e.g., race,
gender, age, sex, and marital status), scheduling history (i.e., number of previous
cancellations, previous appointments, and past treatment protocols), and medical
treatment patient data to make the treatment deferral/no-show predictions for each
patient. This model was chosen based on a comparative procedure, discussed in
Chapter 2, which tested multiple binary decision models to determine the model
with the best out-of-sample prediction based on AUC, Briar Score, and F-1 Score.
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With a decision threshold of probability .75, we correctly predicted 93% of completed
appointments and 21% of deferrals/no-shows with an overall accuracy of 84%. We
note that while a false negative is not ideal, there is no waste cost associated with
it (i.e., the drug would be mixed as planned.) However, a false positive could result
in a drug being wasted if pre-mixed. We emphasize that the UMRCC system was
used as an example case study. The presented computational experiments utilized
historical data from 2016 and expert opinion from the UMRCC pharmacy to estimate
model inputs and validity. We note our modeling approach can be replicated for
other facilities with minor modifications to the pharmacy process flow as well as the
appropriate data sources. After observing the simulated no pre-mix case discussed
in Section 4.4, it was determined a reasonable estimate if the pharmacy did not
pre-mix based on the observed data. We highlight that we focus on comparing
various make-ahead policies as a proof of concept.
4.3.2 Modeling Conditions
The infusion center pharmacy opens at 6:00 am to complete all pre-mix drug
orders. We assume that all pre-mixed orders will not expire before they are
administered if the patient appointment is at noon or before (most drugs have an
8-12 hour lifetime). At 7:30am they finish pre-mixing and begin making orders as
patients arrive (earliest appointment time is 7:30am). We assume if a drug is pre-mix
that it will be completed in this window of time. This is when our simulation starts
and runs until all patients are served each day. The simulation only considers a single
arrival stream of patients based on their appointment time in infusion. There are
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some cases when a same day appointment can occur but the majority of appoints will
be scheduled ahead of time. The simulation then models a single drug order for each
patient with a drug compounding probability of failure of 5%. Through observations
and interviews with pharmacists, we found this to be a reasonable assumption. There
is also a chance for pre-mixed orders to be wasted if a patient defers or doesn’t show.
We assume constant patient volumes for each iteration of the simulation buy vary
them by day of week to best represent the cancer centers current schedule.
4.4 Computational Experiments
We present three tractable and easily implementable pre-mix policies. Then
we compare their performance with the baseline scenario (i.e., no pre-mix policy).
Table 4.2 and 4.4 highlight our performance metrics (total time in system and staff
utilization) compared across scenarios. Since staffing is out of the scope of this
paper, we keep a constant schedule across all scenarios based on the current staffing
schedule at UMRCC. We simulate a week (i.e., Monday through Friday) with a
constant amount of pre-mixed drugs each day since the pharmacy has the same
limited time to pre-mix drugs each day. This week was simulated 20 times to insure
our average drug order time in system metric stayed within an error of 4 minutes for
all days and scenarios based on a 95% confidence level. We first ran 10 iterations of
our simulation to determine our sample mean and standard deviation of the average
drug order time in system. We then utilized the t-distribution to find the number of




In the first scenario, we only consider pre-mixing drugs for the first 20 (this
number is adjustable and dependent on the time allotted for pre-mix) patients who
have a probability of deferral/no-show of 0.1 or lower. This threshold is used as an
example; it is ultimately determined by the decision maker, depending on their risk
tolerance. The probability of deferral/no-show for patients scheduled to receive the
drug orders were determined using a BART model with the input data mentioned in
Section 4.3.1.
4.4.2 Scenario 2
For our second scenario, we disregard the probability of deferral/no-show and
focus solely on patient appointment times when deciding to pre-mix. Since the
pharmacy schedule is heaviest before noon, we focus on pre-mixing only for patients
with scheduled appointments from 8am-12pm . This also ensures that all pre-mixed
drugs won’t expire before the patients’ appointments. Next, we determine the
proportion of appointments in each hour block from the first appointment until noon.
This proportion is used to determine the number of pre-mixed drugs in a respective
hour block (e.g., suppose from 8-9am there are 20 patients out of a total of 100 that
morning, then given we can only pre-mix 20 drugs, the first 5 drugs in that time
window will be pre-mixed).
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4.4.3 Scenario 3
In our last scenario, we combine ideas from both Scenarios 1 and 2. Using the
proportions for each hour block determined in Scenario 2, we then only assign the
allocated number of pre-mixed drugs to patients that fall below the probability of
deferral/no-show threshold from Scenario 1. This policy should incorporate the
benefits of pre-mixing throughout the first half of the day while being more risk
adverse in regards to wasting drugs. This also may spread out the appointments
that have pre-mix drugs (assuming the first five patient in our previous example do
not all fall under the probability of deferral/no-show threshold).
4.4.4 Results/Discussion
Referring to Table 4.2 and 4.3, it is clear that pre-mixing chemotherapy drugs
has a significant impact on a drug orders average time in the system and the
percentage of patients waiting past the goal TAT of 1 hour as Scenarios 1, 2, and 3
all outperform the No Pre-mix case. On Day 3 we see that Scenario 1 out performs
Scenario 2. This is an example where being more risk-seeking by not considering the
probability of deferral/no-show had less reward (i.e., drugs may have been pre-mixed
for patients who actually deferred treatment resulting in no benefit for pre-mixing)
for the patients. However, all other days we see Scenario 2 dominates 1. This results
from Scenario 1 only mixing the first 20 drugs that fit the criteria. This reduces
the potential propagated time savings compared to spreading the pre-mixed drugs
throughout the schedule. While not always significant, we see that the average time
in system for Scenario 3 and the average number of wasted drugs is lower than
88
Scenarios 1 and 2. We hypothesized this to be the case since Scenario 3 is a more
efficient r̈ule of thumbp̈olicy by utilizing the more conservative approach of Scenario
1 but also by lightning the pharmacy load throughout the morning instead of just in
the first couple of hours similar to Scenario 2. While the average percentage of drug
order TATs greater than 1 hour in Scenario 3 slightly increases for days 1,4, and
5, it is not by a significant amount compared to the improvements on the heavier
day 3 with 153 drug orders compared to 121, 116, and 129 from scenarios 1, 4, 5
respectively.
Drug Order Time in System and Wasted Drug Results
Metrics Scenarios
Day of Week No Pre-mix 1 2 3
1 Average 52.79 30.7 26.64 26.17
C.I. (49.51, 56.07) (29.53, 31.87) (26.23, 27.05) (25.65, 26.68)
2 Average 85.63 46.6 41.73 38.19
C.I. (80.79, 90.46) (44.43, 48.8) (39.21, 44.25) (36.19, 40.19)
3 Average 58.04 35.44 37.69 27.47
C.I. (54.74, 61.34) (33.65, 37.22) (34.87, 40.51) (26.59, 28.35)
4 Average 38.1 24.78 22.82 22.43
C.I. (36.3, 39.89) (24.18, 25.37) (22.35, 23.33) (22.06, 22.81)
5 Average 47.86 28.32 25.73 25.7
C.I. (44.95, 50.78) (27.53, 29.09) (25.27, 26.19) (24.71, 26.7)
Avg # of drugs wasted per day 0 2.81 3.13 2.32
Table 4.2: Contains the comparison of time in system for the various scenarios in
minutes
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Percent of Patient’s Drug Orders with TAT >1 Hour
Metrics Scenarios
Days # of Orders No Pre-mix 1 2 3
1 121 Average 34.38 7.23 1.53 1.94
(Min, Max) (20.66, 52.07) (2.48, 19.01) (0, 4.96) (0, 3.3)
2 168 Average 77.65 50.57 35.71 35.45
(Min, Max) (71.43, 82.74) (36.31, 66.67) (16.07, 61.9) (16.67, 52.38)
3 153 Average 59.41 19.31 29.29 5.78
(Min, Max) (33.33, 76.47) (5.88, 36.6) (13.68, 53.57) (.65, 14.37)
4 116 Average 27.63 5.56 1.34 2.07
(Min, Max) (17.24, 37.93) (1.72, 16.38) (0, 3.45) (.86, 4.31)
5 129 Average 43.76 7.13 3.06 4.26
(Min, Max) (31.78, 61.24) (2.33, 22.48) (0, 10.08) (0, 12.4)
Table 4.3: Average, maximum, and minimum percentage of patient who wait past
the 1-hour TAT after running 20 iterations of the simulation
Looking at Day 2 (highest drug order demand day of the week) in Table 4.4, we
also notice a significant effect on staff utilization. For example, both Verification
Pharmacists and Printing Technicians have a very high utilization in the No Pre-mix
case. By simply pre-mixing 20 drugs before the patient rush, we are able to decrease
their utilization by almost 10% and 5% respectively. This supports the idea that
pre-mixing chemotherapy drugs will benefit both the patients and the staff to better
ensure safe delivery of such high hazardous drugs. Since we assume the same
distribution for mixing all chemotherapy drugs and that arrivals are appointment
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driven, the utilization across all pre-mix policies is relatively the same. We note
that our utilization calculation for the Safety Check Pharmacist are an extreme
under-estimate since we were only able to capture the start time for compounding a
drug to the completed time. As seen in Figure 1.2, this also incorporated the Remote
Safety check which is performed by the Safety Pharmacist. It is here where almost all
of the 5% of failed drug orders are determined and cycled back for re-compounding.
Refer to Appendix C for utilization results on all other days.
Day 2 Utilization
Resource Scenarios
No Pre-mix 1 2 3
Avg. CI- CI+ Avg. CI- CI+ Avg. CI- CI+ Avg. CI- CI+
Verification Pharm 0.89 0.8 0.99 0.82 0.77 0.87 0.81 0.77 0.85 0.81 0.77 0.86
Print Tech 0.71 0.56 0.85 0.65 0.62 0.67 0.65 0.61 0.69 0.65 0.62 0.68
Mix Tech 0.3 0.28 0.32 0.28 0.27 0.29 0.26 0.25 0.27 0.27 0.26 0.28
Safety Pharm 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Table 4.4: Utilization comparison between policies on Day 2 of our simulation as
percentages
4.5 Conclusion
Using discrete event simulation, we evaluated various pre-mix policies to
determine which most benefited both the individual patients and the entire
outpatient infusion system. We used estimated probabilities of deferral/no-show
from our BART model to develop these policies for chemotherapy drugs at an
outpatient chemotherapy infusion center pharmacy. These experiments were not
meant to determine the best approach for UMRCC but to demonstrate the idea of
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pre-mix as a technique that can be utilized by other institutions. The discussed model
serves multiple purposes both for our current and future work. While we can test
current r̈ule of thumbp̈olices as done in this paper, we also can evaluate optimization
models that determine, within a fix window of time, what set of drugs are optimal
to pre-mix to minimize the expected time in system as well as expected waste cost.
Our immediate next steps will incorporate the drug cost into the simulation model
as well as introduce additional patient arrival streams from those with a clinic visit.
Future extensions will also allow for more dynamic policies to be tested that provide
unattainable improvements from a static model. This work provides an invaluable
tool to both engineers and medical professional working to reduce patient waiting
time in an outpatient chemotherapy infusion center by helping insure the safety of





In this dissertation, we proposed three methods which, in conjunction, generate
and evaluate make-ahead chemotherapy drug policies (i.e., pre-mix policies) at an
outpatient chemotherapy infusion center.
In Chapter 2, we developed a predictive model to determine the probability a
patient will defer their treatment on a given day. We described the comparative
procedure used during the modeling selection process and emphasize this selection
process must be repeated if applied in another hospital setting. We found a patient’s
previous number of cancelations and the number of days since the patient’s last visit
had the most positive influence on predicting a treatment deferral. Conversely, a
patient’s appointment length, previous number of infusion center visits, and which
treatment regimen they were on had the strongest negative influence on predicting a
treatment deferral (i.e., higher the value the greater chance a patient will not defer).
Future research directions include exploring additional data re-sampling methods
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(e.g., synthetic data generation, stratified sampling) and additional classification
models such as Naive Bayes and support vector machines. We also suggest to explore
additional forms of feature selection that are not limited to stepwise selection and
variable importance, as done in this dissertation.
In Chapter 3, we utilized the patient probability of deferral from Chapter 2 in
our IP models to determine the optimal set of drugs to pre-mix given a fixed window
of time. We introduce two versions of the problem with their respective model
formulations. The CPIP Model assumes all drugs pre-made will last (no expiration)
for the entire day. While this model provides a fast and valuable solution, we found
its limitations include not considering drugs with varied expiration or hang-by times
affected the accuracy of our results. We then introduced the CPIP-HT model which
incorporated drug hang-by time in determining the optimal set of drug to pre-mix
and when to mix them. This model also allows for further extensions of considering
pre-mixing drugs for multiple days given the capacity and required expirations dates.
The CPIP-HT formulation addresses the time dependence and interdependences
between pre-mixing multiple doses of the same drug ( i.e., when the nth dose is
pre-mixed will affect the probability of waste of any subsequent dose). We show our
new model remains tractable in many realistic instances of the problem.
We emphasize that our objective function from both models captures a
conservative estimate on how much wait time is saved for patients prescribed the
pre-mixed drugs. In practice, these time savings would propagate through the
system benefiting many patients. Utilizing the simulation model from Chapter 4,
we evaluated our CPIP-HT relying on the same parameters from our computational
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experiments using a two minute discretization for our time units from Section 3.5.2.
Table 5.1 and 5.2 display the results of our implementation. In Table 5.1 we
reported the average between 20 iterations of the total time in system for each
drug order. The CPIP-HT model suggested pre-mixing from 25-27 drugs each day,
resulting in an estimated 40% reduction in our total time in system metric on average.
This time directly reflects the amount of time a patient must wait (either in the
waiting room or the infusion chair) for their drug. Additionally we measure the
number of patients who waited longer than 1 hour for their drug order in Table 5.2.
At the time of our study, this was the goal turn-around time for the pharmacy. Our
simulation estimates on average a 70% decrease in this metric. In Chapter 4, showed
how strategically selecting which drugs to pre-mix based on when their prescribed
patients with a low probability of deferral are scheduled to receive their drug proves
to benefit patient time savings even more than our model. This led us to a potential
next step of introducing time depended rewards for pre-mixing chemotherapy drugs
in the CPIP-HT model.
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Average Patient Observed Drug Order Time in System (min)
Metrics Scenario
Days No Pre-mix CPIP-HT
1 Average 52.79 28.39
CI (49.51, 56.07) (27.04, 29.74)
2 Average 85.63 51.88
CI (80.79, 90.46) (49.85, 53.91)
3 Average 58.04 29.42
CI (54.74, 61.34) (28.24, 30.61)
4 Average 38.10 24.07
CI (36.3, 39.89) (23.26, 24.87)
5 Average 47.86 37.63
CI (44.95, 50.78) (36.14, 39.12)
Table 5.1: Comparison of simulated results of using the CPIP-HT model to the not
pre-mixing at the UMRCC for a single week
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Average Percent of Patients Drug Orders Past 1-Hour TAT Goal
Metrics Scenarios
Days # of Orders No Pre-mix CPIP-HT
1 121 Average 34.4 6.7
(Min, Max) (20.66, 52.07) (0, 14)
2 168 Average 77.6 41.0
(Min, Max) (71.43, 82.74) (31.5, 53.8)
3 153 Average 59.4 6.4
(Min, Max) (33.33, 76.47) (1.3, 13.7)
4 116 Average 27.6 2.7
(Min, Max) (17.24, 37.93) (.86, 5.2)
5 129 Average 43.8 25.0
(Min, Max) (31.78, 61.24) (14, 33.3)
Table 5.2: Percentage of patient that waiting longer than the 1 hour goal
TAT. We compare the results from the no pre-mix case to using the CPIP-HT
recommendations
Based on these results, we determine one potential next steps of defining a
time-dependent parameter representing the value on reduced wait time when a
drug is pre-mixed. This allows the decision maker to weight pre-mixed drugs for
patients scheduled during peak hours higher than patients schedule at less congested
times of the day to potentially better decrease the load on the system during that
time. Additional next steps include performing a sensitivity analysis on all input
parameters to gain further insights on how our model outputs might change with
another patient population.
In Chapter 4 we introduced a pre-mix policy evaluation tool which utilizes
discrete-event simulation methods as well as the probabilities of patients’ deferrals
97
determined in Chapter 2. We demonstrated the benefits of pre-mixing chemotherapy
drugs by simulating make-ahead ”rule-of-thumb” policies. We also used this tool to
support the idea that pre-mixing a drug not only benefits the prescribed patient, but
also benefits other subsequent patients as we lighten the load on the system during
infusion peak hours. Lastly, we compared the results from a realistic instance of the
CPIP-HT model from Chapter 3 with the no pre-mix base case. Potential next steps
involve exploring simulation optimization methods to generate more robust pre-mix
policies that can be utilized throughout the day rather than just a fixed period of
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Percentage of Deferrals in each Region
Figure A.1: Here we illustrate the proportion of patients that deferred vs completing
their appointment broken down by each region. The total number of patient
encounters in each region are as follows: Region 1 – 35 , Region 2 – 30, Region
3 – 98, Region 4 – 27491, Region 5 – 31, Region 6 – 42, Region 7 – 42, Region 8 –
95, Region 9 – 8
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Figure A.2: Here we have a map of the United States displaying the location of
each region (i.e., the first digit of a zip code) taken from [51]
A.2 Modeling Process
In Figure A.3, we walk through the predictive modeling process. We note that
some of these steps are dependent on the type of response variable (e.g., classification
or continuous).
A.2.1 Data Exploration
In healthcare, data exploration can be one of the most lengthy processes. Due
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Figure A.3: An overview of the modeling process
Common problems include getting data with missing values, inconsistent naming
conventions, or errors occurring from manual data entry. Using tools such as R or
Excel are extremely useful when initially cleaning the data. When working with
a large dataset, simply removing the entire entry or row with an error can suffice.
In some cases this error may be consistent in a particular variable. Removing the
variable completely can help solve the issue but then there is a risk that a significant
predictor is left out.
Next, it is always good to plot the data and review the summary statistics. This
can be used to help catch any errors. For example, if one of the predictors is scheduled
appointment length for infusion and the observed mean is 5 minutes, then something
may have gone wrong while collecting/cleaning the data since appointment lengths
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have a much higher average. Plots can also help to better understand the data and
the relationships between various predictors.
While not as important as using tree based methods, checking for
correlation/collinearity in your data is important when trying to fit a model. For
example, if the model includes both the weight and BMI of a patient, some correlation
issues may arise since the two predictors are closely related. If using a linear model
then this can lead to non-unique beta values. This will make it difficult to make
any inferences from the fitted models. The data can also be standardized to help
interpret the influence of a particular variable directly from the beta values. This is
especially useful if the predictors are on drastically different scales.
A.2.2 Model Formulation
The application and type of response you are looking to predict will help
determine which models you should test on your data. In our case we are dealing
with a binary classification model. This leads us to explore methods such as logistic
regression, classification trees, and other ensemble methods (e.g. Random Forrest
and Bagged Classification Trees).
Next, you can select your variables. If you have a small number of predictors, it
is best to group various subsets and test them all in the hold-out analysis. This way
you ensure yourself to find the optimal variable set. However, most problems have a
large number of predictors which lead us to conduct variable selection directly in the
hold-out since it is not practical to test all subsets of variables. Depending on the
model, R has many packages to help with this. Either utilizing variable importance
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or simply performing a step wise selection.
A.2.3 Hold-out Analysis
If your goal is to select a model with the best predictive performance, then the
hold-out design is one of the most important steps. A poorly designed hold-out can
lead to a biased model that may perform well predicting on your current data set but
poorly on a future data set. First, as done in this paper, you can immediately hold
out a portion of the data for final testing. Next, it is good to split your data into a
training set and a testing set. All models are then fitted to the training set and use
the predictors from the testing set to make a prediction. These predictions are then
compared to the actual response from the testing set to determine the prediction
error. These two sets should be randomly selected to prevent a false sense of high
predictive performance. It is typical to run this holdout at least 30 times to be able
to measure the variability in the prediction error for various models.
When dealing with temporal data, you must take care in making sure you do
not train a model on future events and use it to predict past events. For example,
training on a patients 10th visit to predict their 3rd visit could result in a false sense
of superior predictive performance when in reality this would never happen. To
overcome this with our patient appointment data, we created smaller training and
testing sets. The model was then trained on a random 90 consecutive day period
and tested on the following 30 day period.
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A.2.4 Final Model Selection
Finally, you must compare the prediction error and model fitting error for all
tested models and subsets of variables. When comparing multiple models, it is also
important to validate any significant differences between the predictor errors by using
measures such as the Bonferroni pairwise t-test. Once we select a final model, we
then can test it on the initially held out dataset to determine how well our model
would perform in practice. It is also good practice to explore the influence of each












Alglucosidase alfa 12 hours
Alpha1-Proteinase Inhibitor (human) Immediate
Alpha1-Proteinase Inhibitor (human) Immediate
Antithymocyte globulin (Equine) 12 hours
Arsenic 12 hours

























Cytarabine Intrathecal 7 hours
Cytarabine Liposome Intrathecal 3 hours






Daunorubicin citrate (liposomal) Immediate
Decitabine Immediate
Degarelix Immediate



















Imiglucerase Ref: 12 hours
Immune Globulin 12 hours
Immune Globulin 10% liquid 12 hours













Methotrexate Intrathecal 7 hours






































Topotecan IV 12 hours
Topotecan Intrathecal 3 hours
Trabectedin 6 hours
Trastuzumab IV 12 hours
Trastuzumab Intrathecal 7 hours
Ustekinumab 3 hours
Vedolizumab 3 hours





Zoledronic acid 12 hours
Ziv-aflibercept 3 hours
Table B.1: List of Chemotherapy drugs used by the UMRCC’s Pharmacy and their
hang-by and expiration times
Figure B.1: Drug multiplicity count for all drugs at specific doses that go through the
UMRCC pharmacy between March 2015 and March 2017.
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Figure B.2: Drug multiplicity count for all drugs classified as ”high hazard” at specific





This simulation consists of ten queues:
• The order arrival queue (Aq) which contains one entry per patient pharmacy
order and is sorted by actual arrival time of the order into the pharmacy queue
• The order verification queue (Vq) is initially empty but later contains all orders
waiting for verification. These orders are sorted by scheduled appointment time
• The Available-Pharmacists-to-Verify Queue (V Pq) contains one entry for each
pharmacist available for the verification task, sorted by time that they become
available (i.e. when their shift starts or when they have completed a task)
• The print labels queue (Lq) follows a First in First Out (FIFO) policy. This
queue contains an entry for each order after it finishes two verifications
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• The Available-Tech-to-Print Queue (PTq) contains one entry for the single
print tech working during that shift
• The mixing drug queue (Mq) follows a FIFO policy. This queue contains an
entry for each order after finishing printing the labels
• The Available-Tech-to-Mix-Drug Queue (MTq) contains one entry for each
mixing tech available for this task, sorted by the time they become available
• The safety check and sorting queue (Sq) also follows a FIFO policy. This queue
contains an entry for each order after drug mixing is complete
• The Available-Pharmacist-to-Safety-Check- Queue (PSq) contains one entry
for contains one entry for each safety check pharmacist tech available for this
task, sorted by the time they become available
• The Event queue is used to sequentially order and trace all events in the
simulation
These queues are initialized as follows:
• For each drug order, we generate the actual arrival time from a perturbation
of the scheduled arrival time (i.e. some patients arrive before and some after
the scheduled appointment time). Each order is then placed into Aq,
• All order with an actual arrival time before the start-of-operations are placed
into Vq by order of their appointment time
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• V Pq, PTq, MTq, and PSq are then generated based on the staff schedule for
all pharmacy techs and pharmacist.
• If a drug is pre-mixed, skip to step 6 below
Next we continue to loop through the following steps until we work through the
entire arrival queue:
1. Any drug order with an actual arrival time at or before the simulation clock
time will then move into the verification queue.
This queue is then sorted by scheduled appointment time
2. Verification pharmacist then take the order from the top of the queue to
complete service. After the first verification is complete, the order is then
placed back in the verification queue with a higher priority than the orders
who have not received a first verification yet.
3. Next the order must go through a second verification done by a different
pharmacist than their first verification. After the second verification, the drug
order is then sent to the print labels/drug kit queue.
4. Print techs than take orders in their queue at a first come first serve basis.
After service is complete, the order along with all supplies are placed in the
drug mixing queue.
5. Mixing tech again grab the orders by FIFO and start working on the drug.
There is a chance the tech makes a mistake which is caught by one of the
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safety checks. If this is the case, the tech must re mix the entire drug. After
mixing service is successfully completed. The drug is placed into the sort/safety
check queue
6. Another group of pharmacist will pull from the sort/safety check queue by
FIFO. Once this service is complete the drug is ready for the patient.
Next we present the additional staff utilization tables
C.2 Pharmacy Staff Utilization Tables
Utilization Day 1
Resource Scenarios
No Pre-mix 1 2 3
Avg. CI- CI+ Avg. CI- CI+ Avg. CI- CI+ Avg. CI- CI+
Verification Pharm 0.65 0.61 0.69 0.54 0.51 0.58 0.54 0.52 0.57 0.54 0.52 0.55
Print Tech 0.52 0.49 0.54 0.43 0.41 0.45 0.43 0.41 0.45 0.43 0.40 0.46
Mix Tech 0.21 0.20 0.21 0.17 0.16 0.18 0.17 0.16 0.17 0.16 0.16 0.17
Saftey Pharm 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01





No Pre-mix 1 2 3
Avg. CI- CI+ Avg. CI- CI+ Avg. CI- CI+ Avg. CI- CI+
Verification Pharm 0.87 0.83 0.90 0.76 0.72 0.80 0.75 0.70 0.80 0.75 0.72 0.79
Print Tech 0.69 0.66 0.72 0.60 0.57 0.63 0.60 0.57 0.63 0.60 0.58 0.63
Mix Tech 0.28 0.27 0.29 0.25 0.23 0.26 0.23 0.23 0.24 0.24 0.23 0.25
Saftey Pharm 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01




No Pre-mix 1 2 3
Avg. CI- CI+ Avg. CI- CI+ Avg. CI- CI+ Avg. CI- CI+
Verification Pharm 0.56 0.51 0.61 0.46 0.42 0.51 0.46 0.42 0.51 0.46 0.41 0.51
Print Tech 0.41 0.34 0.47 0.34 0.28 0.39 0.33 0.28 0.39 0.33 0.28 0.38
Mix Tech 0.19 0.18 0.20 0.16 0.15 0.16 0.15 0.14 0.16 0.15 0.14 0.15
Saftey Pharm 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.00 0.01





No Pre-mix 1 2 3
Avg. CI- CI+ Avg. CI- CI+ Avg. CI- CI+ Avg. CI- CI+
Verification Pharm 0.69 0.64 0.73 0.58 0.55 0.62 0.58 0.55 0.62 0.58 0.54 0.62
Print Tech 0.55 0.52 0.58 0.47 0.44 0.50 0.46 0.44 0.49 0.47 0.45 0.49
Mix Tech 0.22 0.22 0.23 0.20 0.19 0.21 0.19 0.18 0.20 0.19 0.19 0.20
Saftey Pharm 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Table C.4: Utilization comparison between policies on day 5 of our simulation as
percentages
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